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Background: Testing and evaluating new HIV prevention products such as HIV vaccines, requires 
identifying, enrolling and retaining cohorts of HIV high risk individuals. This thesis describes the 
recruitment and follow up of high-risk females for participation in HIV prevention trials in Tanzania. 
Specifically, the thesis describes a cohort of female sex workers (FSWs) in Dar es Salaam recruited for 
participation in an upcoming HIV vaccine trial- known as PrEPVacc vaccine trial, as well as changes 
in sexual risky behaviours in a similarly high-risk cohort from northern Tanzania. 
Methods: Between October and December 2018, FSWs aged 18–45 years were recruited using a 
Respondent Driven Sampling method. They were screened for eligibility and 700 of them were enrolled 
into the PrEPVacc registration cohort in Dar es Salaam. At screening and at 3 monthly follow-up visits, 
social demographics, HIV risk behavioural assessments and collection of blood samples for HIV testing 
were done. Qualitative interviews were conducted to explore contraceptive use. Data from a separate 
cohort of high-risk women from Northern Tanzania was used to explore changes in sexual behaviour 
and its association with HIV incidence. 
Results: The baseline HIV prevalence in the PrEPVacc registration cohort was 7.6% (59/773, 95% CI; 
5.8%-9.7%). There were 21 HIV seroconversions over a 12 month follow up period. The HIV incidence 
rate was 3.45 per 100 person-years-at-risk (PYR) (95% CI; 2.25-5.28/100 PYR). The HIV incidence 
rate was higher among FSWs aged 18-24 years (4.31/100PYR), those using illicit drugs (4.25/100PYR) 
and those diagnosed with either Syphilis or Hepatitis B/C virus (10.04/100 PYR). (Study I). 
Nearly half (49%) of high-risk women enrolled in the cohorts from northern Tanzania did not change 
their sexual behaviour practices after 12 months, while 25% had higher risk practices after 12 months 
of follow up. The proportion of women reporting multiple partners, transactional sex and high-risk sex 
practices declined at each 3 months visit (33%, 43% and 47% reduction in odds per visit respectively, 
p for linear trend <0.001 for all). There was no evidence of an effect of change in sexual behaviour on 
HIV rate after adjusting for other factors (adjusted odds ratio (aOR) 0.88 95%CI 0.39-2.01, P=0.76) 
(Study II). 
In the PrEPVacc registration cohort, awareness of HIV pre-exposure prophylaxis (PrEP) increased from 
67% at cohort enrolment to 97% after 12 months (p<0.001). Willingness to use PrEP was high at both 
time points (98% vs 96% p=0.84). Only 8% (57/700) of the FSWs reported to have ever initiated PrEP 
use over the 12 months follow-up period. Use of PrEP was independently associated with: marital status 
i.e married/cohabiting (aOR) 4.19; 95%CI 1.44-12.18) or separated/divorced/widowed (aOR 2.38; 
95%CI 1.17-4.83) and engaging in sex with a HIV infected partner (aOR 3.98;1.20-13.15) (Study III). 
FSWs in the PrEPVacc registration cohort reported that sex work impedes good contraceptive behaviour 
because; FSWs felt unable to negotiate consistent condom use, avoided health services due to stigma, 
missed monthly contraceptive supplies because of inconvenient clinic operating hours and skipped 
contraceptive pills when intoxicated after taking alcohol. Financial hardships related to child rearing 
and painful abortion experiences influenced FSWs’ commitment to good contraceptive behaviour 
(Study IV). 
Conclusions: The high HIV incidence among FSWs in the PrEPVacc registration cohort demonstrates 
that this population is suitable for participation in HIV vaccine trials. The HIV incidence may decline 
over time because of reduction in sexual risky behaviour practices and increased PrEP uptake.  
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Globally, substantial success has been made in the reduction of HIV/AIDS associated 
morbidity and mortality, following the wide spread use of antiretroviral therapy. However, 
there has been slow progress in the reduction of new HIV infections. The UNAIDS goal of 
reducing the number of new HIV infections to 500,000 globally by 2020 was not achieved. An 
estimated 1.7 million people were newly infected with HIV in 2019, more than three times the 
UNAIDS goal (1). The sub-Saharan Africa region disproportionately continues to bear the 
highest global burden of the pandemic and contributed 59% of all new HIV infections in 2019. 
HIV infections rates are high among women living in sub-Saharan Africa and in high risk 
population groups which include, men who have sex with men, people who inject drugs, as 
well as sex workers and their clients (1). Hence highly effective HIV prevention interventions 
especially those that offer control to females are essential so as to reduce HIV incidence and 
curb the HIV epidemic. 
 
The HIV prevention intervention profile has been evolving rapidly in the past two decades. 
These include use of condoms, voluntary medical male circumcision, risk reduction 
counselling, testing and treatment of sexually transmitted infections as well as interventions 
that address structural risk factors e.g., stigma. At the centre of biomedical HIV prevention 
interventions is the use of antiretroviral based prevention i.e. Treatment for Prevention (TasP) 
and Pre-Exposure Prophylaxis (PrEP). However, there are some challenges with the use of 
antiretroviral therapy in order to achieve HIV epidemic control (2). First, broad implementation 
of universal HIV testing and treatment face logistical and financial challenges (3, 4). Second, 
attaining population level viral suppression through universal treatment is unlikely to achieve 
HIV elimination at a population level because access to HIV care is often limited in HIV high-
risk populations who are largely responsible for the HIV transmission (4, 5). And third, even 
when PrEP is accessible, uptake may be low because some of the available highly effective 
PrEP agents don’t work or are not desired by HIV high-risk population groups because of poor 
adherence, stigma or side effects associated with the use of PrEP (6, 7). Therefore, the use of 
antiretroviral therapy as prevention will not be sufficient to reduce the number of new HIV 
infections (8-10). Thus, research to accelerate the development and efficacy testing of a long 
lasting, preventive vaccine remains a priority in controlling the HIV epidemic (6, 8, 10-12). 
 
Of all the HIV vaccine trials conducted worldwide to date, seven have progressed to Phase III 
efficacy trials (8, 13-19). The RV144 Thailand study of (ALVAC-prime, VaxGen rgp120/alum 
boost) is the only trial ever to show modest efficacy of 31% (95% CI 1%–52%) (16). Outcomes 
from the HIV vaccine trials have highlighted that the identification of key immunological 
correlates for protection against HIV and genetic variability of the HIV virus are the key 
challenge for the development of a HIV vaccine (6, 20, 21). Apart from this, there is also a 
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challenge in identification and inclusion of populations with high HIV incidence for evaluating 
vaccine efficacy (21-23).  
 
This thesis describes the epidemiological considerations in recruiting, enrolling and following 
up participants in cohorts being prepared for participation in HIV prevention trials. The focus 
of this thesis is high-risk females which includes women self-identifying as sex workers as well 
as those not self-identifying as sex workers even though they sell sex to supplement their 
income. Together these high-risk women make a suitable population of HIV prevention trials 
because they experience high-risk sexual exposures from multiple sexual partners. Both 





2 LITERATURE REVIEW 
2.1 HIV EPIDEMIOLOGY 
2.1.1 The global burden of HIV  
The global HIV trend shows that the pandemic is declining but the disease burden is still high. 
Although the HIV associated mortality and morbidity are declining, the number of new HIV 
infections is still high globally. In 2019, an estimated 38 million people were living with HIV 
worldwide and about 4500 people were newly infected with HIV every day (1). 
 
The burden of HIV is disproportionately distributed by geographical location, gender and in 
high-risk population groups. Eastern and southern Africa contributes the highest burden with 
20.7 million people living with HIV in the region. Women and girls in sub-Saharan Africa 
accounted for 59% of all new HIV infections in the region in 2019 (1). This may reflect that 
the HIV prevention interventions have disproportionately not reached this population or that 
the available interventions have not worked.  
 
Globally, 62% of all new HIV infections in adults occur among most-at risk populations also 
known as key populations (1). HIV Key populations include adolescent girls and young 
women, men who have sex with men, sex workers and people who inject drugs. Female sex 
workers have the highest HIV infection rate attributable to heterosexual transmission. A meta-
analysis that included studies published between 2007 and 2011 from 50 low-and middle 
income countries reported an overall HIV prevalence among female sex workers to be 12% 
(24). In this meta-analysis, the pooled odds ratio for HIV infection among female sex workers 
compared to women of reproductive age was 13.5 (24). Another meta-analysis that included 
data between 2006-2017 reported that female sex workers living in Eastern and Southern Africa 
have the highest HIV prevalence estimated at 33.3% (5). As of 2019, the UNAIDS estimated 
HIV prevalence among female sex workers in this region to range from 10.4% in Eritrea, 33% 
in Uganda to 57.7% in South Africa (1). Figure 1 shows a map of the world with the 2019 
UNAIDS estimates of HIV prevalence among female sex workers. 
 
Encouragingly, the number of new HIV infections has been decreasing globally over the past 
decade. This decline of new HIV infections has been attributed to the 38% reduction in new 
HIV infection among women in southern Africa. This reduction is higher than the global 
average of 28% reduction in new HIV infections (1). Therefore, controlling the heterosexual 
HIV transmission in women in southern Africa especially among female sex workers is the key 




Figure 1 Estimates of HIV prevalence among female sex workers in 2019. 
Source UNAIDS: https://aidsinfo.unaids.org 
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2.1.2 The epidemiology of HIV in Tanzania 
The overall HIV epidemic in Tanzania has had an encouraging downward trend in the last 
decade, following the wider national coverage of antiretroviral treatment programmes as well 
as other interventions. The HIV prevalence among adults aged 15 to 49 years has decreased 
from 5.7% in 2007/2008 to 4.8% in 2016/2017 (25, 26). However, the declining trend has 
disproportionately been less among women compared to men within the same age groups. For 
instance, HIV prevalence declined from 4.6% to 3.1% among men and from 6.6% to 6.4% 
among women between 2007/2008 and 2016/2017. Although the increased life expectancy 
attributed to the wide availability of antiretroviral therapy may explain the small decline in the 
HIV prevalence across the years, higher HIV infection rate among females may account for the 
disproportionate and persistent higher HIV prevalence among women.  
 
In the year 2019, there were 1,700,000 people living with HIV in Tanzania and an estimated 
69,000 people were newly infected with HIV (27). The HIV incidence rate in the adult 
population is estimated to be 1.27 infections per 1000 people (27). This incidence rate is above 
the goal of less than 1 per 1,000 adults per year needed to attain HIV epidemic control in the 
country (28-30). However, Tanzania is among countries to have nearly achieved the 2020 
UNAIDS 90-90-90 goal. As of 2019, 83% of Tanzanian living with HIV were aware of their 
HIV status, 75% of those aware of their status were on antiretroviral therapy and 69% of those 
on treatment were virally suppressed (27). 
 
The HIV epidemic in Tanzania is concentrated in certain regions where the prevalence of HIV 
infection is higher. For example, the prevalence of HIV infection varies from 0.3% in Lindi 
region to 11.4% in Njombe region (25). The high HIV prevalence in Njombe region is largely 
caused by the sex-trade along the Tanzania-Zambia highway, a major long-distance truck route. 
HIV prevalence is also high in the Lake zone regions (e.g., Mwanza 7.2%, Geita 5%) because 
of the multiple and concurrent sexual partnerships among the fisher-folk community (31). The 
HIV prevalence in Dar es salaam, the business capital of Tanzania is close to the national 
average (4.3% versus 4.7%). The HIV prevalence in Dar es Salaam is of public health interest 
in the national fight against HIV because the city is densely populated and has the largest 
number of HIV high-risk population group in the country (32, 33). Figure 2 shows a map of 
Tanzania with HIV prevalence across different regions. 
 
Other than geographical variation, HIV prevalence in Tanzania is higher among key population 
groups. Key population groups in Tanzania include, sex workers, men who have sex with men 
and people who inject drugs. HIV prevalence among the high-risk groups in different parts of 
the country is estimated to range from 8% to 42% among people who inject drugs (27, 34, 35), 
15% to 41% among female sex workers (36-38) and 16% to 31% among men who have sex 
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with men (39-42). A study conducted in five regions in Tanzania estimated that 5.6% of 
females and 1.3% of males aged 15-49 years are female sex workers and men-who -have sex 
with men respectively (33). Moreover, there is evidence indicating an overlap of sexual 
behaviours between members of the key population groups and the overall general population. 
Studies indicate that at least half of men who have sex with men in Tanzania have concurrent 




Figure 2 HIV prevalence among adults aged 15 years and older, by region in Tanzania 
Source: Tanzania HIV Impact Survey 2016-2017 
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 Sex work context in Tanzania 
Sex work, generally defined as exchange of sex for money, goods or other favours (43, 44), is 
diverse and operates in various contexts. There are many types of sex work but generally 
divided into “direct” and “indirect” sex work (43). “Direct” sex workers are those whose 
primary mode of income is through exchanging sex for a fee. “Indirect” sex workers sell sex 
to supplement an income from another lowly paying occupation and many do not self-identify 
as a sex worker. A qualitative study of female sex workers in Tanzania found that there were 
four main forms of commercial sex reported: (a) waziwazi (open or frank) prostitution in which 
women work from their own rooms within a community, (b) employed women supplementing 
their salaries, (c) brothel girls, and (d) streetwalkers (45). There is also a great of variety in the 
social context for selling sex. In Tanzania, sex work based in entertainment places (bars and/or 
night clubs) is most dominant (33). Sex work in lodges and on the streets is also common. 
While some sell sex through formal organized groups (in brothels), others work independently 
and others solicit sex through mobile phones. Women working in bars, guesthouses and 
recreational facilities (bar maids) who supplement their income by offering sex in return for 
money or gifts, form a subset of high-risk women in the country (46). These female bar maids 
often act as indirect sex workers but may not self-identify as a sex worker in contrast to bar 
based female sex workers (46-54). 
 
On the other hand, female sex workers have different kind of partnerships. Partners may include 
(a) regular clients - someone who pays to have sex with the sex-worker on a regular basis, i.e., 
daily, weekly, monthly (b) non-regular/ casual partner with whom only a sex worker has a 
single sexual encounter or several sexual encounters over a short period of time, without the 
expectation of a relationship (c) husband, boyfriend, or steady partner who is someone that the 
female sex worker regularly has sex with, without receiving any cash payments (d) 
transactional partner with whom sex is exchanged for a favour but not for money e.g, a partner 
who may buy her drinks at a bar, a bodaboda driver who gives her a ride or a watch guard who 
alerts her on police raids.  
 
Sex work is criminalized according to the Tanzanian Penal Code (55). Selling and buying of 
sex and sex-work related activities such as facilitating sales, brothel ownership or pimping are 
considered illegal Arrest, police raids and extortion of sex workers are not uncommon in 
Tanzania. Nevertheless, the Tanzanian National HIV Strategic Plan recognizes the need to 




2.2 DETERMINANTS OF HIV RISK AMONG FEMALE SEX WORKERS  
The heightened risk for HIV acquisition among female sex workers is driven by variety of 
behavioural, structural and biomedical factors (5, 7, 24, 57-59).  
2.2.1 Behavioural risk factors 
Female sex workers experience high HIV risk exposure through the high number of sexual 
partners. The HIV risk is increased because some of the sexual partners may be HIV infected 
and not virally suppressed. The report of number, type and time frame of female sex workers’ 
partners in literature is highly varied. In Tanzania, more than half of female sex workers 
reported having two to four sexual partners on the last day they worked (36, 54)  and an average 
of five partners per week (37, 60) . However, it is important to note that female sex workers 
engage in sex work intermittently and that they occasionally take break from sex work (7). 
 
The use of condoms among female sex workers is low and highly dependent on the type of 
sexual partner. Consistent condom use is generally higher with paying regular or non-regular/ 
casual partners as compared to steady/intimate partners (36, 45, 61-63). Condom use at last sex 
is often used as a proxy measure for consistent condom use because of the recall bias and over-
reporting of condom use in studies (64). Estimate of condom use at last sex among female sex 
workers is estimated to be 80% globally (1) and 72% in Tanzania(27, 36). 
Many female sex workers are unable to consistently use condoms because of client refusals. 
Clients may be forceful and sexually assault the sex worker or may offer higher pay to forgo 
condom use (37, 58, 65). Inconsistent condom use is also particularly high among younger 
female sex workers (44, 66), probably because of undeveloped condom negotiating skills or 
greater financial vulnerability. In surveys among female sex workers in Tanzania, consistent 
condom use was reported by 16%-74% of the sex workers (36, 37, 60). 
 
Substance use including hazardous alcohol drinking and illicit drug use are common among 
female sex workers. In Tanzania, 76% of female sex workers surveyed who use alcohol, 
reported having consumed alcohol while conducting sex work (36). Use of substance among 
female sex workers heighten their risk-taking behaviour, reduce their ability to negotiate and 
correctly use condoms and is associated with increased sexual and physical abuse (67, 68).  
 
2.2.2 Biomedical risk factors 
The high prevalence of sexually transmitted infections among female sex workers and the 
synergistic relation between HIV infection and other sexually transmitted infections 
compounds the HIV risk in this population (69). In Tanzania, high rates of sexually transmitted 
infections have been reported among high-risk women including female sex workers working 
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in major cities and in towns around major transit routes. These include Herpes simplex virus 
type 2, Chlamydia infection, bacterial vaginosis and genital ulcers with reported hazard ratio 
(adjusted) for HIV incidence of up to 4.3, 5.2, 2.1 and 2.7 respectively (47, 48, 70, 71). 
 
Female sex workers who also use injectable illicit drugs have a higher risk of HIV infection. 
This is because of the increased parenteral HIV exposure from shared injection equipment. 
Female sex workers who are intoxicated after injecting drugs are also more likely to engage in 
high-risk sex and less likely to use condoms (35, 72). Needle sharing and unprotected sex 
practices further increases their risk to Hepatitis C virus infection as well as other sexually 
transmitted infections. 
2.2.3 Structural risk factors 
Structural factors play a central part in HIV epidemic among sex-workers. There is an overall 
consensus in the literature from the past decade suggesting that even though high-risk sexual 
behaviours play a significant role in increasing new HIV infection in this population, 
interventions targeting only the behavioural and biomedical risk factors have had only a modest 
effect because structural factors underpin the context in which these behavioural and 
biomedical risks operate. Structural factors include poverty, stigma, human rights violation, 
gender inequality, violence against women, criminalization of sex work, inappropriate 
legislation and lack of political will to ensure access to preventive health, HIV services (7, 11, 
24, 73-75). 
 
In a systematic review of structural risk factors for HIV infection among female sex workers 
globally, Shannon and colleagues demonstrated the interrelationship of structural factors with 
behavioural and biological factors to influence HIV risk (57). The authors showed 
criminalization, sex work related stigma, gender-based violence and poverty were associated 
with increased inconsistent condom use and HIV infection, while seasonal migration to areas 
of high burden increased their HIV vulnerability. A study conducted in Iringa Tanzania 
reported the impact of stigma, discrimination and violence among female sex workers on 
impeding engagement of female sex workers with HIV services (37). Similarly, qualitative 
studies done in Iringa Tanzania have reported stigma against sex workers seeking ante-natal 
services (76, 77). 
 
Mobility is also a structural determinant of HIV among female sex workers as it can limit their 
access to and extent of using HIV services when they move across several locations. Female 
sex workers mobility can also have an impact on HIV epidemiology depending on the local 
epidemics of the settings they moved into. Female sex workers commonly move to another 
location in search of seasonal-sex trade opportunities or access a wider potential market for 
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clients in case of festivals. For example, female sex workers participating in a qualitative study 
in Northern Tanzania reported travelling away from their usual work locations for periods of 
one week to a month for better pay, some travelling to higher HIV prevalence setting such as 
fishing sites, mining or highways (31, 48). Indeed, in that the study, female sex workers 
reported that most men at the fishing sites preferred and paid higher for condom-less sex and 
therefore increase risk of HIV transmission. 
2.3 CONTRACEPTIVE USE AND UNINTENDED PREGNANCY AMONG 
FEMALE SEX WORKERS 
Access to reproductive healthcare including contraceptives, is an essential component of the 
comprehensive HIV prevention services for female sex workers. Nevertheless, several studies 
have reported a large unmet contraceptive need in this population (60, 76, 78). This unmet need 
has been evident from the high rates of unintended pregnancy in this population (79-83), high 
abortion rates (79, 81, 83, 84) and the expressed desire to prevent future pregnancies (77, 85). 
Access to family planning offers an opportunity for female sex workers to harness other HIV 
interventions including PrEP, condoms, risk reduction counselling, diagnosis and treatment of 
sexually transmitted infections. 
2.3.1 Contraceptive use among female sex workers 
The use of dual methods of contraception i. e condoms together with a modern non-barrier 
contraceptive method among female sex workers living in Dar es Salaam is very low, at 5.3% 
(60). This is lower than the 40% reported in other cities in sub-Saharan Africa (86, 87). Among 
female sex workers, the use of injectable and oral contraceptive pills methods is much more 
prevalent as compared to the use of long-acting reversible contraceptives such as Intra-uterine 
devices and Implants (88, 89). Although all the contraceptive methods are effective with correct 
use, dual contraceptive use with long-acting reversible contraceptives are advocated for female 
sex workers (90). This is because of their adherence advantage as they are less prone to 
incorrect use, discontinuation or frequent switching (12, 80, 87).  
2.3.2 Unintended pregnancy among female sex workers 
Incidence of pregnancy among HIV high risk females is reported to range from 12-18 per 100 
person-years of exposure in Tanzania (52, 91) and up to 20 per 100 person years of exposure 
in other African settings (92, 93). Most of the pregnancy among female sex workers are 
reported to be unintended or unplanned. In a study among female sex workers in Uganda, 65% 
reported their pregnancy to have been unplanned (82). Factors associated with unintended 
pregnancy among female sex workers include being impregnant by a casual (non-emotional) 
partner, experiences of rape and substance abuse (78, 82, 83). 
 
Unintended pregnancy among female sex workers is of public health concern because of the 
economic and social implications which may intensify the HIV risk associated with sex work. 
For instance, because of the financial burden associated with child rearing expenses, money 
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becomes a powerful incentive for forgoing condom use or engaging in other forms of high-risk 
sex (77, 94, 95). Also, unintended pregnancy that ends up in abortion contribute to the maternal 
mortality burden (96).  
 
Thus, unintended pregnancy among female sex worker can be a proxy measure for poor sexual 
health as it may reveal lack of access to contraceptive services. It may also reflect challenges 
in adhering to the available contraceptive methods e.g., failure to negotiate consistent condom 
use and failure to adhere to daily pill taking. These challenges are explored and discussed in 
this thesis. A reflection on how existing barriers to contraceptive use among female sex workers 
and how these can inform better ways to deliver services in this population is provided in the 




2.4 BIOMEDICAL HIV PREVENTION INTERVENTIONS 
Table 1 provides a summary of the available biomedical HIV prevention interventions, 
evidence for their efficacy and status of implementation where applicable. Globally, the 
portfolio of biomedical HIV prevention interventions is rapidly changing (6, 97). Biomedical 
HIV prevention interventions include; male and female condoms, medical male circumcision, 
testing and treatment of sexually transmitted infections, immediate initiation of antiretrovirals 
among infected persons so as to reduce their infectiousness (Treatment as Prevention, also 
known as TasP), the use of antiretrovirals among uninfected individuals to prevent acquiring 
infection (Pre-Exposure Prophylaxis, also known as PrEP) as well as use of antiretrovirals 
following inadvertent HIV exposure (Post exposure Prophylaxis, also known as PEP). The use 
of antiretroviral drugs as PrEP can either be as oral tablets, long acting injectables, vaginal 
rings, vaginal or rectal gels. Of all the available HIV prevention interventions, this section will 
mainly focus on PrEP and HIV vaccine products as they are relevant in this PhD thesis.  
 
The use of daily oral PrEP pill consisting of tenofovir disoproxil fumarate in combination with 
emtricitabine (also known as Truvada©,) has been shown to be safe and efficacious for HIV 
prevention in both men and women (98-103). Efficacy trials which included diverse high-risk 
populations (including female sex workers) have found PrEP to reduce HIV incidence by over 
90% when used consistently (100-102, 104-106). Following these evidence, in 2015 the World 
Health Organization recommended Truvada to be used among populations with an HIV 
incidence greater than 3 per 100 person years of observation (107). Another tenofovir based 
antiretroviral therapy that has been recently approved for use as an oral PrEP is Descovy©, 
which contains emtricitabine and tenofovir alafenamide. Recent efficacy trials (The Discover 
Trial) showed that the use of Descovy was non inferior to Truvada and that Descovy had less 
renal and bone toxicity compared to Truvada (108). However, Descovy has not been 
sufficiently assessed among heterosexual females living in sub-Saharan Africa. Descovy would 
be tested for the first time as part of the PrEPVacc vaccine trial which is described in this thesis.  
 
Apart from the daily oral PrEP formulation, there are other long-acting PrEP products available 
or under research. Dapivirine vaginal ring is an antiretroviral based PrEP that has been found 
to be safe, efficacious and acceptable in two phase III trials. This is a silicon vaginal ring that 
is worn for a month and contains the dapivirine antiretroviral drug. The use of the dapivirine 
ring was found to reduce HIV infection risk by 30% to 91% depending on adherence (109-
112). In 2020, the use of the dapivirine vaginal ring was recommended by European Medicine 
Agency and the World Health Organization for use among women aged 18 and older 
particularly in southern Africa. Other long-acting PrEP products includes a 8 -weekly injectable 
Caboltegavir which has been shown to be safe and effective in a Phase III trial (113-116). 
Islatravir is a long acting PrEP which has completed phase II trials assessing its use as a 
monthly oral tablet and trials are ongoing assessing its use as an yearly implant (117). 
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There are three ongoing HIV vaccine efficacy trials evaluating vaccine immunogens designed 
elicit protective responses against global HIV-1 subtypes. The Imbokodo study (HVTN 705) is 
a Phase IIb vaccine efficacy trial evaluating the safety and efficacu of a prime regimen 
consisting of Ad26.Mos4.HIV and aluminium-phosphate adjuvanted Clade C gp 140 in 
reducing HIV incidence among women at high HIV risk in Southern (118). The Mosaico study 
(HVTN 706) is a Phase III vaccine efficacy trial that evaluates the same immunogens (used in 
the Imbokodo study) among men having sex with men and transgender individuals in America 
and Europe (119). The third trial is the PrEPVacc trial a Phase IIb which aims to compare two 
HIV vaccine products DNA-HIV-PT123+ AIDSVAX and DNA, modified vaccinia Ankara 
Virus and envelope protein plus adjuvant alongside two pre-exposure prophylaxis (Descovy 
and Truvada) (120). The major part of this thesis will discuss the preparation of a cohort of 
high-risk females recruited for participation in the PrEPVacc vaccine trial at Dar -es Salaam 
site.  
 
In summary, by the end of the year 2020, there were several ongoing efficacy trials evaluating 
biomedical HIV prevention products. These include HIV vaccine products, passively infused 
monoclonal antibodies and antiretroviral based PrEP in different formulations i.e. oral pill, 
injectables, vaginal ring and implants. Figure 3 provides a summary of some of the ongoing 
efficacy trials of biomedical products for HIV prevention. The level of efficacy varies and the 
evidence for these products is constantly evolving. In these studies, the trial design includes 
combining a previous established efficacious biomedical product (such as Truvada as an oral 
PrEP) with new or partially effective product. This combination is ethically required as a 
standard prevention package so as to minimize HIV risk among study volunteers. As a result, 
designs of HIV vaccine trials include an active control arm whereby participants receive a high 
efficacious PrEP agent instead of a placebo. This design results in reduction of HIV incidence 
events and hence lower the statistical power of the study needed to detect efficacy of the 
vaccine product. This thesis will highlight some of the problems and methodological 




Table 1 Summary of HIV biomedical intervention and supporting evidence 
Intervention Evidence of efficacy  
Male condoms Up to 80% efficacy when used correctly and consistently (121). 
Female condoms No data from HIV efficacy trials 
Testing and treatment of other sexually 
transmitted Infections 
There is strong evidence from observation studies on an increased risk of HIV in the presence of a sexual 
transmitted infection(122); However there is lack of evidence from randomized clinical trials on the effect of 
treatment of sexually transmitted infections in reducing the risk of HIV infection (9, 123, 124). 
Post Exposure prophylaxis 
Effectiveness has been established from observational studies and are supported by studies in non-human primates 
(125). Randomized clinical trials in humans are unethical. 
Treatment as prevention (TasP) 96% protective efficacy among sero-discordant partners (126). Mixed trial results on the effect of "universal test and treat" strategy in reducing HIV incidence at population level (2, 3, 127, 128). 
Antiretrovirals drugs as pre-exposure prophylaxis (PrEP) 
Tenofovir based oral daily PrEP Up to ~96% efficacy when used consistently (100, 104-106). Recommended for use in high-risk populations 
Tenofovir 1% topical vaginal gel 2% to 54% efficacy depending on adherence (105, 129, 130). No subsequent trials or licensure in progress. 
Dapivirine Vaginal ring  
(Long-acting PrEP) 30%-92% efficacy depending on adherence (109-112). Recommended for women 18 years and older. 
Caboltegravir Injectable  
(Long-acting PrEP) 
66% -89% more effective than Truvada  in preventing HIV infection (113, 114). 
HIV vaccine candidates 
ALVAC-HIV + AIDSVAX subtype B/E 
gp120/alum vaccine regimen 
HVTN 702 (RV144 Thai Trial) Estimated vaccine efficacy of 61% through 12 months and vaccine efficacy of 31% 
through 42 months (16, 131).The modified vaccine regime for the subtype C epidemic in southern Africa was 
stopped in 2020 because non efficacy. 
 
Broad Neutralizing antibodies (bNab)  
A proof of concept trial as demonstrated that long term infusion with broad neutralizing antibodies (VRCO1) is 






Figure 3 Summary of biomedical HIV prevention clinical trials as of November 2020 




2.5 HIV VACCINE TRIALS IN TANZANIA: LESSONS LEARNT AND 
KNOWLEDGE GAPS 
Tanzania began to prepare for the conduct of HIV vaccine trials in the early 1990s. Preparation 
included recruitment and assessment of a police officers’ cohort for participation in HIV 
vaccine trials (134). Laboratory infrastructure including virological and immunological 
capacity for evaluating vaccine immunogenicity were established at the Muhimbili University 
of Health and Allied Science (MUHAS) with support from the Swedish International 
Development Agency (Sida). This was done together with the training of clinical researchers, 
laboratory scientists, pharmacists and socio-behavioural scientists. Over the years, the MUHAS 
HIV Vaccine Clinical Trial Unit was established as a research site for the conduct of HIV 
vaccine trials.  
 
A total of five Phase I/II HIV vaccine trials assessing safety and immunogenicity of vaccine 
products have been conducted at the MUHAS HIV Vaccine Clinical Trial Unit between 2007 
and 2015. These include HIVIS-03, HIVIS-06, TaMoVac I, TamoVac I+gp140 and TaMoVac 
II (135-142). 
 
The HIVIS-03 study was a Phase I/II randomized, double-blinded placebo- controlled clinical 
trial conducted from 2007 to 2010. The study enrolled 60 healthy, HIV uninfected adults. 
Participants were randomised into three arms to receive either three doses of a multiclade, 
multigene HIV-1 DNA plasmid vaccine intradermally (low dose), intramuscularly (higher 
dose) or a placebo followed by two boosts of a heterologous HIV-1, modified vaccinia virus 
Ankara (MVA) boost. The study found that priming with a low intradermal dose elicited a 
higher and broader cell-mediated immune response as compared to the higher priming dose 
given intramuscularly (136).  
 
The HIVS-06 study was a Phase II study conducted from March to May 2012. The study 
intended to explore the durability of the immune response from the second HIV-1 MVA boost 
received in HIVIS-03 and the effect of a late, third boost given three years later. In the trial, 
twenty volunteers from HIVIS-03 who had received the HIV-DNA prime/HIV-MVA boost 
regime described above were enrolled. They were given a third boost of HIV-1 MVA, three 
years after the last boost had been received. The study found that potent antibody and cellular 
immune responses persisted for three years in 74% of vaccinees. It also found that the third 
dose of HIV-MVA significantly boosted both antibody and cellular immune responses to a 




The TaMoVac I study was a Phase IIa randomized, placebo controlled doubled blind trial 
conducted from 2008-2012. The study enrolled 129 participants who included police officers 
and prison services officers. The trial explored whether HIV-DNA priming can be simplified 
by reducing the number of injections and compared the administration of a combined versus 
separate plasmid pools. Participants were randomized to three arms to receive either 5 
injections of HIV-DNA (1000 μg total dose of 3 Env and 2 Gag encoding plasmids) or two 
simplified regimes of 2 injections of HIV-DNA (600 μg total dose of Env- and Gag-encoding 
plasmids) administered separately or combined. The study found that the simplified regime 
comprising of 2 injections of low HIV-DNA dose of combined HIV-DNA plasmids was as 
efficient as the standard regime of 5 injections which had a total dose of 1000 μg (137). 
 
The TaMoVac I+gp140 was conducted in 2012 whereby, forty volunteers (thirty-five 
vaccinees and five placebo recipients) from the TaMoVac I study were given two boosts of a 
subtype C CN54rgp140 envelope protein adjuvanted in glucopyranosyl lipid. The study 
intended to evaluate the safety and impact of the boost given after 30 to 71 weeks after the last 
HIV-MVA vaccination. The study found enhanced binding antibody responses and Env- 
specific cell mediated immune response among vaccinees but there was no increase in the 
antibody-dependent cellular cytotoxicity (140). 
 
The TaMoVac II included 191 healthy, HIV uninfected vaccine recipients and was conducted 
between 2012 and 2015. The trial aimed to assess safety and immunogenicity of DNA priming 
administered using an electroporation and whether this method would reduce the number of 
vaccination doses needed to achieve immune response. Participants were first randomized to 
two arms to receive a HIV- DNA prime with or without an intradermal electroporation. They 
were concurrently randomised to receive HIV-MVA boost given together with or without the 
subtype C CN54rgp140 envelope protein adjuvanted in glucopyranosyl lipid. The study found 
that the intradermal electroporation increased DNA induced Gag response but had no impact 
on the Env-specific responses. There was enhanced antibody responses among those who 
received HIV-MVA with rgp140/ glucopyranosyl lipid A (139). 
 
In summary, findings from the HIV vaccine trials conducted at MUHAS showed that the DNA 
prime and the MVA boosting strategy was safe and highly immunogenic. The vaccines were 
further optimized by simplifying the DNA regimen, applying novel delivery methods and 
adopting better boosting strategies.  
 
A side from the clinical trials, auxiliary social-behavioural studies which were conducted 
during the trials showed that there was high willingness among individuals to participate in 
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HIV vaccine trials. Majority of the participants were motivated by altruistic reasons of being 
part of HIV vaccine development while others participated because they believed that the trial 
would offer protection against HIV infection (143-145). Reasons for declining participation 
included personal fears and negative influences by significant others including sexual partners, 
friends and immediate family members (145-147).  
 
Another notable experience from the HIVIS-03 trial, was the low recruitment and poor 
retention of female volunteers (148). This was because the study required that a volunteer 
should not conceive during the entire study duration. During the study, four volunteers (4.5% 
of all screened) became pregnant and had to exit the study. Based on this experience, this thesis 
will discuss on facilitator and barriers to contraceptive use among female sex workers enrolled 
in a registration cohort being prepared for participation in the PrEPVacc vaccine trial. 
 
Through all the HIV vaccine trials, Tanzania has had a platform to train laboratory and clinical 
research personnel to conduct advanced HIV vaccine trials. The laboratory capacity built over 
time has accorded MUHAS the infrastructure to conduct all necessary laboratory analyses 
needed to support Phase II HIV vaccine trial locally. The MUHAS HIV vaccine clinical trial 
unit established during these trials will be used to conduct the PrEPVacc vaccine trial discussed 





3 AIMS AND OBJECTIVES OF THE THESIS 
3.1 AIM 
The overall aim of this thesis was to determine the feasibility of recruiting female sex workers 
for participation in HIV vaccine trials. The PhD studies intended to determine the HIV 
incidence and associated behavioural risk factors for HIV acquisition as well as to assess 
reproductive health needs among HIV high-risk females participating in HIV preventions trials 
in Tanzania.  
3.2 SPECIFIC OBJECTIVES 
1. To estimate the HIV prevalence, the one-year HIV incidence and factors associated 
with HIV sero conversion among female sex workers in Dar es Salaam, Tanzania. 
2. To describe the changes in sexual behaviours and factors associated with risky 
behaviour changes after one-year of follow-up among women enrolled in HIV 
prevention trials in Northern Tanzania. 
3. To assess awareness, willingness and use of HIV pre-exposure prophylaxis among 
female sex workers in Dar es Salaam, Tanzania. 
4. To explore experiences of unintended pregnancy and contraceptive use among female 
sex workers in Dar es Salaam, Tanzania. 
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4 THESIS FRAMEWORK 
The conceptual framework for this thesis addresses research questions in two key areas—HIV 
risk and HIV prevention interventions among female sex workers (Figure 4 and 5). The 
research questions, interpretation of results and description of ethical considerations are 
discussed with reference to the three levels of HIV risk among female sex workers— 
behavioural, biomedical/biological and structural risks. On the other hand, the thesis discussed 
behavioural, biomedical and structural HIV prevention interventions among female sex 
workers, although an emphasis is made on biomedical HIV prevention interventions. 
The research studies in this thesis explored the heightened risk of HIV acquisition among 
female sex workers that is driven by a combination of behavioural, biomedical and structural 
risk factors which transcend those for the general population (7, 24, 57). Data collected across 
the studies included variables from all three risk levels. The research studies also explored 
behavioural, biomedical and structural HIV prevention interventions (58, 149). The HIV 
prevention interventions for female sex workers discussed in this thesis include; use of 
antiretroviral based for HIV pre-exposure prophylaxis (PrEP), screening and treatment of 
sexually transmitted infections (as biomedical intervention), consistent condom use, risk 
reduction counselling and HIV testing (as behavioural intervention) and access to sex-worker 
friendly reproductive health services (as structural intervention).  
Paper I is the central paper that provides an estimate of the HIV burden among female sex 
workers (prevalence and incidence) and associated behavioural, biomedical/biological and 
structural risk factors. The paper explored the contribution of behavioural factors (e.g., number 
of sexual partners), biomedical factors (e.g., co infection with sexually transmitted infections) 
and structural factors (e.g., sexual violence). 
Paper II is linked to the HIV behavioural risk factors and the behavioural interventions. This 
paper assessed sexual risky behaviour practices and explored if reduction in risky behaviours 
occurs over time among women receiving risk-reduction counselling. It further explored if the 
reduction in risk behaviours is associated with a reduction in the HIV incidence. 
Paper III explored PrEP as a biomedical intervention. The paper explored PrEP awareness, 
willingness and use among female sex workers. It also explored determinants of PrEP use in 
this population. 
Finally, Paper IV mainly explored structural risk factors that influence sex workers’ capacity 
to choose and use products to protect against unintended pregnancy as well as sexually 
transmitted infection including HIV. This paper explored how factors such as sex-work stigma 
in health care settings impede access to contraceptives and how sex workers fail to negotiate 









Figure 5 Thesis framework liking the study research questions to the levels of HIV prevention interventions among female sex workers 
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5 MATERIALS AND METHODS 
5.1 OVERVIEW 
The PhD research studies included in this thesis utilized both qualitative and quantitative 
research methods. Figure 6 below provides a summary of the research objectives, study 
populations, study design and sample size used for each paper. The study populations for the 
PhD studies included HIV high-risk females enrolled in cohorts being prepared for 
participation in HIV prevention trials in different parts of the country. Study I, III and IV were 
conducted among female sex workers recruited between 2018-2020 into the PrEPVacc 
registration cohort in Dar es Salaam, Tanzania. Study II was conducted among high-risk 
women recruited between 2008-2010 into the microbicide and vaccine feasibility studies in 
northern Tanzania. The map of Tanzania in Figure 7 shows the study areas for the parent 
cohorts of the different PhD studies.
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Figure 7 Map of Tanzania showing the study areas 
Vaccine and microbicides feasibility studies: Kapiga et al PLoS One (2013) 
The PrEPVacc registration cohort: ClinicalTrials.gov. (NCT04066881) 
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5.2 STUDY SETTING 
This section provides a description of parent cohorts from which the PhD studies were 
conducted. The description on the PrEPVacc study is provided in sections 5.2.1 whereas the 
Microbicide and Vaccine feasibility cohort study conducted in Northern Tanzania is described 
in sections 5.2.2.  
Three PhD studies (Study I, II and IV) were conducted as part of a HIV vaccine trial preparation 
cohort, i.e the PrEPVacc registration cohort in Dar es Salaam (120, 150) while Study II was 
conducted as part of the microbicides and vaccine preparedness cohort studies conducted in 
Northern Tanzania (71). 
5.2.1 The PrEPVacc registration cohort 
Studies I, III and IV were conducted within the PrEPVacc registration cohort — a vaccine 
preparedness study at MUHAS, Dar es Salaam Tanzania.  
 
PrEPVacc is a collaborative partnership between European and African research and academic 
institutions, funded through the European and Developing Countries Clinical Trials Partnership 
(EDCTP). The PrEPVacc research has two components, first the registration cohort — in 
which the PhD project was nested and second, the PrEPVacc HIV vaccine trial.  
 
The PrEPVacc vaccine trial is a multi-centre, phase IIb, three-arm, two-stage randomized trial 
that will evaluate the effectiveness of combining pre-exposure prophylaxis (PrEP) with two 
HIV vaccines in preventing new HIV infections (121). The PrEPVacc vaccine trial sites include 
Masaka (Uganda), Maputo (Mozambique), Durban and Verulam (South Africa), Mbeya and 
Dar es Salaam (Tanzania). 
The PrEPVacc trial will have two-stage randomization. The first will be a three-arm 
prospective 1:1:1 randomisation comparing two experimental vaccine combination regimens 
with a placebo control. Participants will receive either a combination of the DNA-HIV-PT123 
and AIDSVAX® B/E HIV vaccines at weeks 0,4,24 and 48 (Group A), or a combination of 
DNA-HIV-PT123 vaccine and CN54gp140 followed by boosting with Modified Vaccinia 
Ankara-Chiang Mai Double Recombinant (MVA-CMDR) and CN54gp140 adjuvanted with 
Monophosphoryl lipid A (MPLA-L) (Group B) or a saline placebo (Group C). The second and 
concurrent two arm 1:1 randomisation will compare two regimes of pre-exposure prophylaxis, 
either daily Descovy or daily Truvada in the first 26 weeks of immunization. Figure 8 provides 





At each of the PrEPVacc vaccine trial sites, a registration cohort of HIV negative individuals 
at high risk for HIV infection were established. The main objectives of these cohorts were to 
estimate the HIV incidence and facilitate enrolment into the PrEPVacc vaccine trial. At the Dar 
es Salaam site, secondary objectives for the cohort included: estimating the prevalence of 
Syphilis, Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infections, ascertaining the 
knowledge, perceptions, uptake of and adherence to PrEP, ascertaining the knowledge, 
perceptions, and willingness to participate in HIV vaccine trials, developing and refining key 
messages about HIV vaccines and PrEP as well as tools for conveying these messages and 
educate participants about, PrEP, HIV vaccine research in general and the PrEPVacc vaccine 
trial in particular. 
 
The PrEPVacc Registration cohort in Dar es-Salaam is conducted at the MUHAS HIV Vaccine 
Clinical Trial Unit. The study site is located within the National referral hospital, Muhimbili 
National Hospital. The site offers linkage and referral of participants to HIV care and treatment 
clinic, family planning clinic, Hepatitis clinic as well as Methadone assisted therapy located 
within the Muhimbili National Hospital. A total of five phase I/II HIV vaccine trials have been 
conducted at the study site (135-142) as described in the section 2.5 of this thesis. The study 
site is easily accessible through public transport. The study clinic has quiet and private rooms 
to ensure participants’ confidentiality and limited distraction. The clinic has designated rooms 
which have restricted access for storage of completed case report forms. Biological specimens 
are collected at the site and transferred to be stored at the MUHAS’s Microbiology and 
Immunology laboratory.  
Week -6 0 1 4 5 8 16 24 26 30 38 48 50 62 74 ….. 2022/23
Vaccination
• Arm A: DNA-HIV-PT123 plus AIDSVAX B/E at Week 0, 4, 24 and 48
• Arm B: DNA-HIV-PT123 plus CN54gp140/MPLA at week 0 and 4, MVA-CMDR/CN54gp140/MPLA at week 24 and 
48
• Arm C: Saline at week 0, 4, 24 and 48 
Provision of Descovy or Truvada
Endpoint for PrEP Analysis Endpoint for Interim Vaccine Analysis
Every 12 weeks 
for HIV Testing
Blood Draws. HIV testing/store are week -6, 0, 4, 8, 16, 24, 26, 30, 38, 48, 62, 74, every 12 week during LTFU
Immunological Samples
Figure 8 Study schema for the PrEPVacc vaccine Trial 
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5.2.2 The microbicide and vaccine cohorts in northern Tanzania 
The microbicide and vaccine preparedness cohort studies were established between 2008-2010 
in northern Tanzania. The vaccine feasibility study was conducted in Moshi town while the 
microbicide feasibility study in the northern lake zone towns of Geita, Shinyanga, and Kahama. 
Geita and Kahama towns have large-scale gold mines while Shinyanga has a diamond mine. 
The mines are a large attraction for men seeking jobs and consequently sex workers migrate to 
these areas. Moshi town is along a major highway connecting northern Tanzania with Kenya. 
Moshi town is also along the slopes of Mountain Kilimanjaro, a key tourist destination in 
Tanzania and hence the town has large number of hotels and guesthouses. Together, the cohort 
studies recruited women who worked in bars, guesthouses, hotels and other food and 
recreational facilities in the selected towns. Women working in these facilities are known to 
supplement their income by selling sex to clients and hence highly vulnerable to HIV and other 
sexually transmitted infections (47, 51, 70, 151, 152).  
 
The two cohorts were established as additional sites for recruiting larger study populations 
needed to participate in vaginal microbicides trials and HIV vaccine trials. These studies were 
part of the Microbicides Development Programme collaboration whose aim was to develop 
and evaluate effective vaginal microbicides. At the time, a phase III microbicide study of the 
PRO-2000 vaginal gel was ongoing however, this trial was later stopped for lack of efficacy 
(153). It was anticipated that future trials within the Microbicides Development Programme 
collaboration may need to compare new products or combinations of earlier products which 
had shown limited efficacy i.e using active control group. Based on the anticipated need for 
larger sample size, the European and Developing Countries Clinical Trials Partnership 
(EDCTP) had funded the establishment of new cohorts that might be used in future microbicide 
or HIV vaccine trials.  
The microbicide and vaccine preparedness cohort studies from northern Tanzania did not 
proceed into efficacy trials as initially intended. Participants in these cohorts were later on 
enrolled into clinical trials evaluating the effect of treatment of sexually transmitted infections 
in reducing HIV risk (154). The cohorts have also been evaluated to assess suitability of this 
population for participation in other HIV prevention trials (52, 92, 155). Information on 
recruitment, follow-up and retention of women in these cohorts has helped inform the design 
and conduct of PhD studies included in this thesis.  
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5.3 STUDY POPULATIONS AND RECRUITMENT OF PARTICIPANTS 
The research studies in this PhD thesis utilized two study populations to answer the research 
questions. Study I, III and IV included female sex workers enrolled in the PrEPVacc 
registration cohort in the Dar es Salaam region. Study II included women enrolled in the 
microbicide and vaccine feasibility studies in northern Tanzania (Figure 6 and 7). Section 
5.3.1 describes the study population and recruitment for participants included in studies I and 
III, section 5.3.2 describes the study population and recruitment of participants in study II 
whereas section 5.3.3 describes recruitment of participants for study IV. 
 
5.3.1 Study population and recruitment of participants for Study I & III.  
Study populations for study I &III were female sex workers enrolled in the PrEPVacc 
registration cohort in Dar es Salaam. The cohort included women self-identifying as street, 
home or brothel-based sex workers living in Dar es Salaam. They were eligible for inclusion if 
they met the following criteria: aged 18 to 45 years, reported to have exchanged sexual 
intercourse for money within the past month, considered by the investigator to be at increased 
risk for HIV infection, willing to undergo pregnancy testing, HIV pre and post-test counselling, 
resided within Dar es Salaam, able and willing to provide written informed consent. Table 2 
below provides a list of the PrEPVacc registration cohort inclusion and exclusion criteria. 
Table 2 Inclusion and exclusion criteria for cohort enrolment into the PrEPVacc 
registration cohort 
Inclusion criteria 
• Women aged 18-45 years at enrolment  
• Willing and able to give informed consent 
• Willing to undergo HIV testing at screening, and receive their HIV test result 
• Willing to have regular urine pregnancy tests 
• Not planning to move away from Dar es Salaam for the next 12 months 
• Willing to provide adequate locator information for tracking and willing to be 
contacted by the study staff  
Exclusion criteria 
• HIV-positive 
• Current participation in another HIV prevention study that may reduce HIV 
incidence  
• Any condition(s) that in the opinion of the investigator, might make it difficult for 





 Respondent driven sampling for recruitment of participants for Study I & III 
Between October and December 2018, a total of 775 female sex workers were recruited from 
whom 700 were eligible and consented to enrol into the PrEPVacc registration cohort. Female 
sex workers were recruited using Respondent Driven Sampling (RDS). This is a special 
sampling method used to recruit marginalised and hard-to reach population such as the female 
sex workers. The respondent driven sampling methodology has been previously described in 
literature (156-159). This method has been used successfully to recruit female sex workers for 
participation in surveys within Tanzania (36, 160, 161) and in other settings (162, 163).  
Respondent driven sampling began with selection of “seeds” who are members of the female 
sex workers community in Dar es salaam and known by the study investigator. The seeds were 
selected purposively to represent the diversity of female sex workers in Dar-es- Salaam. The 
diversity of the seed included the following parameters; district of the work area, age and HIV 
status i.e one known HIV positive female sex worker was included as a seed. Seeds were 
provided with three study coupons and instructed to recruit peers who were aged 18 to 45 years 
and lived in Dar es Salaam. Participants recruited by the seeds (wave one) were also provided 
with three coupons to further recruit other peers (wave two). This process was continued until 
the number of eligible participants consenting to enrol into the PrEPVacc registration cohort 
reached the estimated sample size. Recruiters and their recruits were linked by unique 
identifiers written on their recruitment coupon. Figure 9 shows an illustration of recruitment 
chains from a single seed in respondent driven sampling. 
  
Figure 9 Illustration of recruitment chain in respondent driven sampling 





A research assistant who was a female sex worker vetted recruits to confirm that they were sex 
workers by asking questions about number of sex acts, client meeting points and specific 
idioms used by the female sex worker community. Potential participants with valid recruitment 
coupons were provided with study information and procedures in Kiswahili. Thereafter, willing 
participants were required to sign an informed consent form. The study nurses and doctors 
performed the eligibility screening procedures using eligibility assessment case report forms 
based on criteria in Table 2. 
A total of 8,000 Tanzanian Shillings (Equivalent to 3.50 US dollars) and 4000 Tanzanian 
Shillings (Equivalent to 1.7 US dollars) were paid to each participant for transport 
reimbursement and as incentive for successful recruitment of a peer. 
 
5.3.2 Study population and recruitment of participants for study II.  
The study population for study II was women enrolled in the microbicide and vaccine 
preparedness cohort studies in northern Tanzania. Both cohorts included HIV negative women 
aged 18 to 44 years working in food and recreational facilities. These facilities included, bars, 
restaurants, guesthouses, hotels, entertainment venues, shops selling traditionally brewed beer 
and food vendors.  
 
Recruitment was done in stages, with a separate screening and enrolment visit. First, mapping 
of recreation facilities was done to obtain an approximate count of women working at these 
facilities. Meetings were held at facilities to provide information on the research and to invite 
women to participate in the study. Following the mapping, clusters that would be able to recruit 
250-330 women were created and a study clinic was established in each cluster. Women 
working in the recreational facilities were invited to attend a screening visit at the study clinic. 
If they satisfied a number of eligibility criteria, they were invited to return to the clinic one 
month later for study enrolment. Eligibility criteria included: willingness to undergo HIV 
testing and to receive the result, a HIV negative result, and likely to be resident in the study 
community for one year. Further eligibility check and written informed consent were 
performed for women returning for the enrolment visit. They were interviewed and data on 
socio-demographic and behavioural characteristics were collected. Participants also underwent 
genital examination and collection of genital samples. Women enrolled in the study were asked 





5.3.3 Study population, recruitment of participants and sample size for 
Study IV (qualitative study)  
Study IV included female sex workers who had a positive urine pregnancy test at the time of 
enrolment into the PrEPVacc registration cohort (between October and December 2018). A 
pre-determined sample size of 18 diverse female sex workers was considered sufficient to 
answer the research question. The 18 female sex workers were purposively sampled out of 32 
(sampling frame) who had a positive urine pregnancy test during study enrolment. The 
sampling of study participants considered demographic and phenomenal considerations so as 
to purposefully maximize diversity of the informants (164). Young and older sex workers were 
selected to reflect variations in their years of experience in sex work as well as their sexual and 
reproductive health history. Parity and past contraceptive use were the phenomenal 
considerations used during sampling. Participants were invited for an interview by a female 
research assistant who was part of the PrEPVacc study team, and well known in the Dar-es- 
Salam sex workers’ community. In-depth interviews were initially conducted with nine of the 
18 sampled women who were willing to participate in the study. Three sampled participants 
could not be reached and six declined to be interviewed (2 were out of town, 1 had a new born 
baby and 3 reported to be busy). Those agreeing to participate were provided with a daytime 
interview appointment that was convenient for them. During data collection two additional 
informants were included in the study making a total of 11 study informants. The two 
informants were considered as “deviant cases” from which, emerging themes could be tested 
to achieve saturation (165). One of the deviant cases was a younger sex worker who had never 
been pregnant. She provided perspective on contraception and abortions from female sex 
workers with no pregnancy experience. The other deviant case, a HIV positive woman was 
included to explore the opinions from preceding informants who had suggested that HIV 
positive sex workers are less likely to use condoms, (therefore more likely to get pregnant) and 




5.4 SAMPLE SIZE AND POWER ESTIMATION FOR QUANTITATIVE STUDIES 
5.4.1 Sample size estimation for Study I 
The sample size estimates for Study I were based on achieving a desired HIV incidence of 4 
cases per 100 person-years after 12 months of follow-up in the PrEPVacc registration cohort— 
and also the primary outcome for Study I. The desired HIV incidence of 4/100 per-years-at risk 
is recommended for trials so as to allow sufficient statistical power in estimating efficacy of 
HIV prevention products (23, 92, 93, 166-169). This desired HIV incidence rate is within the 
observed HIV incidence rate range of 2 to 13 cases per 100 person years in similar cohorts of 
high-risk women in Tanzania and other parts of sub-Saharan Africa (50, 71, 170-175). The 
estimated sample size was adjusted for a 25% expected loss to follow-up rate as female sex 
workers are a highly mobile population. The sample size was also corrected for an expected 
design effect of 2, based on a similar design effect used in respondent- driven sampling studies 
conducted among female-sex workers in Dar es Salaam (36, 160, 161). As shown in Table 3 
below, at power of 80% and 5% significance level, a minimum sample size of 650 was deemed 
sufficient to detect an HIV incidence of 4 cases per 100 person-years after 12 months of follow 
up. The estimated sample size was rounded to 700. 















size (N) Adjusting for 
DEFF of RDS 
studies (Nx2) 
Assuming 
25% LTFUP  
(N x (1/(1-
0.25))) 
4 +/- 3.5 0.5-7.5 161 322 430 
4 +/-3 1-7 244 488 650 
4 +/-2 2-6 630 1260 1680 
4 +/-1 3-5 3221 6442 8589 
Assumptions used to achieve a 12-month HIV incidence of 4% at risk at power 80% and 
5% significance level. DEFF-Design effect; RDS -Respondent driven sampling; LTFUP-
Loss to follow up  
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5.4.2 Power estimations for Study II 
At the study design stage, the primary outcome for study II was HIV incidence at 12 months 
with the main exposure being changes in sexual behaviour after 12 months of follow up. Power 
of 86% was estimated to achieve statistical significance at p<0.05. These estimations were 
based on the assumption that, out of the 1,378 women in the combined dataset, one-third of the 
women would have high risky sexual behaviours. The HIV incidence at 12 month in the group 
of women with high-risk behaviours was anticipated to be 6% compared to 2% in the group of 
women with less-risky sexual behaviours. Due to the small number of HIV cases in the dataset 
(44 cases of HIV seroconversion), the study was deemed to have low statistical power to detect 
the adjusted estimates for the association between changes in sexual behaviours and HIV 
incidence at 12 month (the intended primary outcome). Therefore, preliminary decision was 
made to regard this analysis as exploratory. The results of these exploratory analysis are 
presented in this thesis (in Table 9) but these results are not included in the published paper 
for study II. Table 4 below shows the assumptions for power estimation in Study II. 





























2% 6% 1378 1 95 95 
2% 6% 1378 3 95 86 
2.5% 5.5% 1378 1 95 77 
3% 5% 1000 1 95 42 
N1/N2 sample size ratio – women with risk behaviours and women with less-risky 
behaviours. Assumptions were made that one-third of women in the cohort would 





5.4.3 Power estimations for Study III 
The primary outcome for study III at the study design stage was the proportion of female sex 
workers aware of PrEP at cohort enrolment—that is, out of the 700 HIV negative female sex 
workers enrolled in the PrEPVacc registration cohort. Power to detect this outcome was 
estimated because this was a fixed population i.e analysis performed within the cohort of 700 
HIV negative female sex workers. A power of 100% was estimated to achieve a statistical 
significance at p<0.05 for the proportion of PrEP awareness. These estimations were based on 
the assumption that out of the 700 HIV negative female sex workers enrolled in the cohort, 
two-third of the women would be aware of PrEP. This assumption was based on findings from 
the survey conducted among female sex workers in Dar es Salaam in late 2017(36). In this 
survey, 31% of the female sex workers reported to have ever heard of PrEP (personal 
communication with author). Given the fact that recruitment and enrolment in to the PrEPVacc 
registration cohort took place nearly a year after data collection in the mentioned survey had 
been concluded, it was assumed that the number of female sex workers aware of PrEP would 
have doubled. It was also expected that the number of PrEP users in the cohort would be low 
due to the intermittent supply of PrEP in Dar es Salaam (personal communication with the 
Ministry of health Tanzania). Table 5 below shows the assumptions for power estimations in 
study III. Preliminary analysis of the PrEPVacc registration cohort’s baseline data also showed 
that there were very few female sex workers using PrEP. Therefore, a decision was made to 
estimate power using expected proportion of female sex workers aware of PrEP. Analysis of 
determinants of PrEP use would be regarded as exploratory to avoid statistic errors due to low 
power. Results for determinants of PrEP awareness are presented in this thesis (in Table 10) 
but not included in the manuscript for study III. 
 












0.66 0.76 700 95 100% 
0.66 0.46 700 95 100% 





5.5 DATA COLLECTION 
5.5.1 Data collection for I & III 
This section describes the data collection process in the PrEPVacc registration cohort from 
which data for Study I and III were obtained. 
 Data collection procedures in the PrEPVacc registration cohort. 
Eligible participants underwent face-to-face baseline interviews in private rooms at the study 
site. Information on sexual risky behaviour practices, HIV risk perception, reproductive 
history, drug and alcohol use were collected. Each interview lasted about 30 to 45 minutes. 
Participants were required to provide 10 mL of whole blood for rapid HIV, Syphilis, HBV and 
HCV virus infection detection and 5ml of urine for pregnancy testing. Pre- and post-test 
counselling were performed by trained Nurse Counsellors. Follow-up interviews and HIV 
testing were performed every three months. A summary of the study visit procedures is 
provided in Table 6 below. 
 Laboratory procedures. 
Rapid tests were performed at the study site by a trained Laboratory Scientist and verified in 
the Microbiology and Immunology Laboratory at the Muhimbili University of Health and 
Allied Sciences. The Tanzanian HIV rapid testing algorithm (176) was applied which uses two 
sequential rapid diagnostic tests; SD Bioline HIV1/2 (Standard Diagnostics Inc., Republic of 
Korea) for screening and Uni-Gold HIV-1/2 (Trinity Biotech, Ireland). Participants who were 
reactive to both rapid HIV tests were regarded as HIV infected. ELISA tests; Murex HIV 
Ag/Ab Combination (DiaSorin S.p.A. UK Branch) and Enzygnost. HIV Integral 4 ELISA® 
(Siemens Healthcare, Germany) were used to resolve discordant results between two the HIV 
rapid tests.  
  
Syphilis testing was performed using a Laborex rapid Treponemal assay (Orient Gene Biotech 
Co Ltd, Zhejiang, China) and all reactive samples were confirmed on Treponema Pallidum 
Haemagglutination Assay. Blood samples were tested for Hepatitis BsAg, HBsAb, HBc IgM 
Ab, HBeAg, Hepatitis C virus IgM antibodies. All reactive rapid Hepatitis B and C test samples 
were confirmed using Murex Hepatitis B and Hepatitis C ELISAs (Diasorin S.P.A., Italy), 
respectively. A urine pregnancy testing was performed by detection of β-Human Chorionic 
Gonadotrophin (β-HCG) using (Orient Gene Biotech Co Ltd, Zhejiang, China). HIV-infected 
participants were provided with a referral note and escorted to their preferred health care 
facility to receive free HIV care and treatment. Participants who tested positive for Hepatitis B 
or C were referred to the Hepatitis clinic at Muhimbili National Hospital for further 

















Visit Month 0 3, 9  6, 12  exit  
Provision of study information and 
informed Consent 
x    I, III 
Assessment of eligibility  x    I, III 
Baseline Demographic Questionnaire x    I, III 
HIV Risk and Risk Reduction 
Questionnaire 
x  x x  I, III 
Information on PrEP x  x x  III 
HIV Counselling and Testing  x x x x I 
Testing for Hepatitis B, C virus infection  x    I 
Contraceptive counselling  x x x x I 
Urine pregnancy test x  x x I 
5.5.2 Data collection for study II 
Study II was a secondary analysis of data from the combined cohorts of the vaccine and 
microbicide feasibility studies conducted in northern Tanzania. While I was not involved in the 
data collection of these studies, below I provide a brief description on the data collection 
procedures. An account of my involvement in data cleaning and preparation of the datasets for 
analysis is also provided.  
 Data collection procedures in the microbicide and vaccine feasibility studies. 
Eligible HIV negative women consenting to enrol into the cohorts underwent structured face-
to- face interviews. During the interviews, information on their socio-demographic 
characteristics, employment, reproductive history and work mobility was collected. 
Information about alcohol use was obtained using the four CAGE questions which are used to 
determine alcoholism(177). Alcohol use information was also obtained from the Alcohol Use 
Disorders Identification Test (AUDIT) based on responses from 10 questions (178). Blood 
sample collection was performed for laboratory testing of HIV, syphilis and HSV-2. Clinical 
examination and genital samples were collected for detection of genital infections (Neisseria 
gonorrhoeae, Chlamydia trachomatis and Trichomonas vaginalis). Bacterial vaginosis was 
diagnosed by Nugent’s criteria (179). Participants were followed every three months for 12 
months with similar interviews, clinical examination, and collection of samples performed at 
each visit. Syphilis tests were not performed in the vaccine preparedness cohort (Moshi) while 
N.gonorrhoeae, C.trachomatis and T.vaginalis tests were not done at the 3-month and 9-month 
visits in both cohorts. Participants with positive laboratory tests for curable sexually transmitted 
infections (N.gonorrhoeae, C.trachomatis, T. vaginalis or Syphilis) received free treatment as 
per Tanzanian ministry of health guidelines. 
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 Data cleaning and management for study II datasets 
I was provided with two datasets which had variables related to the study II research question. 
Each dataset contained combined data from the two cohorts. The first dataset contained 
baseline information and the second dataset contained information collected at the 3-, 6-, 9- 
and 12-months follow-up visits. In the baseline dataset, socio-demographic variables included: 
age at enrolment, religion, educational status and marital status. Employment history and work 
mobility variables included: type of work place, average monthly income, history of travel in 
the last 12 months and permanence of residence in the current town. Reproductive history 
variables included: number of lifetime pregnancies and contraceptive methods. Sexual 
behaviour variables included: age at sex debut, number of lifetime partners, number of sex 
partners in the last 1, 3, and 12 months, history of condom use in last sex act, history of condom 
use with regular and/or non-regular partners in the last 3 months, history of transactional sex 
in the last 3 and 12 months, history of anal sex, rape or sex during menstruation in the last 3 
months and perception of HIV acquisition risk. Information on alcohol intake in the last 12 
months was available from both CAGE and AUDIT scores. 
The follow-up dataset contained time-varying exposures measured at 3 monthly follow-up 
visits including: number of partners in the past 1 and 3 months, frequency of condom use with 
regular partners and/or non-regular partners in the last three months (categorized as always, 
inconsistently or never) as well as history of transactional sex, rape, sex during menses and 
anal sex in the past three months. 
 
Minimal data cleaning was performed because the datasets had previously been cleaned for use 
by the principal study investigators. Data checking was performed by summarizing, describing, 
cross tabulating and inspecting the frequency distribution for missing values, extreme data 
values and other inconsistencies. Thereafter, variables were categorized based on the 
distribution so as to minimize data sparsity. History of travel in the last 12 months preceding 
baseline clinic visit was categorised in two groups: No travel (no nights away from home) and 
at least once (continuous week away from home on one or more occasions). Alcohol drinking 
from the 10- item AUDIT score was dichotomized as score <8 points versus ≥8 points (Non-
drinker or low-risk versus Harmful or hazardous drinking) while CAGE score (Cutting down, 
Annoyance by criticism, guilty feeling and Eye-openers) was categorized into three categories: 
0-1 as non-drinker or no problem drinking, 2=possible problem drinking and ≥3 probable 
problem drinking. A “high-risk sex” variable was generated by combining women reporting a 
history of rape, sex during menses or anal sex in the past 3 months.  
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5.5.3 Data collection for study IV 
Study IV used in-depth interviews to collect qualitative data. The choice for using in-depth 
interview instead of focus-group discussion was made because in-depth interviews offer an 
opportunity for the informant to provide a personal account of the unintended pregnancy 
experience as well as an account on the decision-making considerations for contraceptive use. 
Additionally, individual interviews are more ethically accepted for collection of sensitive data 
(165) because both sex-work and abortions are illegal in Tanzania (55). 
 
 Development of the interview guide for Study IV 
During the development of the interview guide, the Health Believe Model (180) was used to 
conceptualize sex work and its relation to unintended pregnancy. The decision to use the Health 
Believe Model in developing the interview guide was based on the theoretical papers in 
behaviour research by Nathason et al (181) and Hall et al (182). In these papers, the authors 
used the Health Believe Model to explain contraceptive behaviour among unmarried young 
women (181) and to explore the determinants of uptake of modern contraceptive behaviour 
(182). Taking these papers together, the Health Believe Model was deemed applicable in the 
context of contraceptive use among female sex workers because; i) pregnancy among female 
sex workers is an undesired condition and therefore avoided— arguably more than in women 
in the general population (ii) decision to use contraceptives e.g. condom for prevention of 
unwanted pregnancy or performing an abortion are directly influenced by multiple sexual 
partners and (iii) contraception behaviour is complex because it includes different action points 
i.e initiation, consistent/correct use and continuation. These action points are influenced by 
perceived benefits and barriers operating at community (structural) and individual levels. The 
components of the Health Believe Model were applied to conceptualize how female sex 
workers use a multidimensional approach to make decisions on using contraceptives and when 
dealing with unintended pregnancy (94). For instance, the interview guide included probes on 
how access to contraceptives versus side effects (perceived barriers) influence decisions to 
initiate or continue contraceptive use. The guide also probed on how sex workers perceived 
their susceptibility to unintended pregnancy given that the decision to use condom was 
influenced by their partners, and if this perceived susceptibility influenced their decision on 
using dual contraceptives (perceived benefit).  
 
The interview guide evolved with subsequent interviews accommodating emerging themes 
based on responses provided by preceding interviews thereby increasing theoretical sensitivity 
(165). The interview guide developed for Study IV include the following thematic areas: 
facilitators and barriers of contraceptive use; experiences related to unintended pregnancies and 
attitudes towards induced abortion.  
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 In-depth Interviews for study IV 
I conducted all the in-depth interviews for the Study IV. All interviews were conducted in the 
local language of Kiswahili. Each interview lasted for about 45 to 60 minutes. They were 
conducted in an isolated room at the PrEPVacc study site. The venue was familiar to the 
informants because they had visited the site for at least three occasions prior to the interview. 
Informants were also familiar with me (the interviewer) because I was part of the PrEPVacc 
study team and was involved in the PrEPVacc enrolment and follow-up interviews. 
 
The In-depth interviews began with a brief personal introduction, explanation of the study aims 
and objectives, signing of consent form and followed by background demographic questions. 
Thereafter, respondents were asked to narrate their experiences and reactions upon receiving a 
positive pregnancy test during enrolment into the PrEPVacc registration cohort. Participants 
were asked to describe their thoughts on how pregnancy affected their sex work. The influence 
of peers, families and partners on unintended pregnancy were also explored. Follow-up 
questions (probes) were asked in order to give a chance to the informants to explain if the recent 
pregnancy had influenced their intentions to use contraceptives in the future. Attitudes towards 
induced abortions were explored among women who had reported to have had an abortion and 
those who had not.  
 
The interview guide was used in a flexible manner so as to encourage informants to speak in 
their own words and therefore allow for new emerging ideas and unexpected information (165). 
Because the interview guide evolved with subsequent interviews, later interviews were more 
focused and covered more concepts albeit risking more narrow and specific responses (165, 
183). For example, the interview with the first informant (in-depth interview conducted in 
January 2019), covered fewer concepts but provided a long and detailed narration of the issues 
whereas the interview with the tenth informant (in-depth interview conducted in June 2019) 
covered more concepts but elicited narrower responses. 
 
All interviews were transcribed and then translated to English. They were all read through to 
obtain the sense of the whole. English translated transcripts were compared with audio files 




5.6 DATA ANALYSIS 
This section provides a description of the study outcomes and the analysis approach for each 
study outcome in the respective PhD study. 
5.6.1 Study I 
 Study outcomes: 
a) Prevalence of HIV, HBV, HCV and Syphilis among all female sex workers screened 
for enrolment into the PrEPVacc registration cohort. 
b) Determinants of the baseline HIV prevalence. 
c) HIV incidence after 12 months of follow up among the HIV negative female sex 
workers enrolled into the PrEPVacc registration cohort. 
d) Determinants of HIV incidence at 12 months. 
 Statistical analysis 
v Outcome(a): Prevalence (proportion) of HIV, HBV, HCV, and syphilis infections among 
all female sex workers screened during recruitment into the PrEPvacc registration cohort 
were estimated. The respective confidence intervals for the prevalence were estimated. 
v Outcome (b): Frequency and percentages were used to describe baseline sexual and 
demographic characteristics. Chi-squared test was used to compare sexual behaviours and 
demographic characteristics between women who tested HIV negative and HIV positive at 
baseline screening. Logistic regression was used to estimate the odds ratios for the factors 
associated with the baseline prevalence of HIV. Using a forward stepwise approach, a 
multivariable logistic regression model was built beginning with the set of significant 
(P<0.20) univariate predictors. Adjusted odds ratios for the factors associated with 
prevalent HIV infection and their respective 95% confidence intervals were summarized. 
v Outcome (c): HIV incidence after 12 months of follow up was calculated as number of HIV 
seroconversions divided by the total persons years of observation. For each infection, the 
date of seroconversion was assumed to be halfway between the last negative and first 
positive results. Data was censored at the earliest seroconversion date for those who became 
HIV infected. For those remaining HIV negative, data was censored at date last seen or at 
12 months. 
v Outcome (d): Factors associated with HIV seroconversion were determined using Poisson 
regression models. Incidences of HIV seroconversion were summarized by rate ratios, 95% 
CI and likelihood ratio test significance value. Due to the few cases of HIV seroconversion, 
only univariate Poisson regression analysis was performed. Nelson-Aalen cumulative 
hazard curves were plotted to compare HIV cumulative hazards between participants with 




5.6.2 Study II:  
 Study Outcomes 
a) Baseline prevalence of risky sexual behaviours among women enrolled in the 
microbicide and vaccine feasibility cohorts. 
b) Changes in sexual behaviours over time among women enrolled in the microbicide 
and vaccine feasibility cohorts. 
c) Association between baseline characteristics and changes in sexual behaviours among 
women enrolled in the microbicide and vaccine feasibility cohorts. 
d) Association between changes in sexual behaviours and the incidence of HIV infection 
at 12 months among women enrolled in the microbicide and vaccine feasibility 
cohorts 
 Statistical analysis 
v Outcome(a): Descriptive statistics including frequencies and proportions were performed 
to determine the distribution of socio-demographic variables and baseline self-reported 
sexual behaviours. Chi-squared tests were used to compare the distribution of socio-
demographic characteristics and sexual behaviours at baseline between younger (aged 
<25 years) and older (≥25 years) women. 
v Outcome (b): Changes in sexual behaviours over time in the cohort was determined in two 
ways, changes at cohort level and changes at individual levels. At cohort level, proportions 
of risky sexual behaviours were summarized for the baseline visit, 3,6, 9 and 12 month 
visits. For each variable, using a random-effects logistic regression model with a random 
intercept, odds for the change in sexual behaviours over time were estimated. For this 
analysis, each sexual behaviour (outcome) was dichotomized and coded 0 for no and 1 for 
yes and the model was adjusted for visit as a linear term (coded as 1,2,3,4,5) to obtained 
odds ratio per study visit. Trends in prevalence over time for each sexual behaviour 
outcome were assessed using likelihood ratio tests, and the p-values were presented. At the 
individual level, changes in risky sexual behaviours was determined using a risk score. The 
risk score was generated from regression coefficients from a Poisson regression model 
which had HIV seroconversion as an outcome. In this analysis, the date of seroconversion 
was assumed to take place midway between the last negative and first positive HIV 
serology results. Women were censored at the earliest date of HIV seroconversion, date 
last seen, or end of follow up. Baseline sexual behaviour factors whose univariate 
association reached statistical significance at p<0.05 were entered into the multivariable 
model. Variables that remained statistically significant in this model were considered for 
inclusion in the development of the risk score. All multivariable Poisson regression models 
were adjusted for age, study area, and marital status as a priori confounders. Selection of 
the “best” multivariable model was based on one that provided negative regression 
coefficients for behaviours known to be protective against HIV infection and positive 
regression coefficients for risky behaviours that increase HIV risk. For instance, a model 
that had a negative coefficient for transactional sex, i.e. indicating transactional sex was 
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protective against HIV acquisition, was considered implausible. This selective approach to 
model building was chosen for two main reasons: (i) so as to generate predicted values for 
the sexual behaviour risk scores in their appropriate category (protective behaviours versus 
harmful behaviours); (ii) with such a small number of HIV seroconversion events (44 HIV 
cases), stringent criteria were needed to select few “key” parameters for the model i.e a 
model with only four co-variates in accordance with the “rule of ten”. The obtained risk 
coefficients were then used to predict and create new variables for sexual behaviour risk 
scores at baseline and 12 months visit, labelled as “Baseline risk scores” and “12 month 
risk scores” respectively. Histograms were used to display the distribution of the values of 
the predicted risk scores and their respective means were summarized. A paired t-test was 
used to compare the means of the baseline and 12- month risk scores. Thereafter, “Baseline 
risk score” and “12 month risk score” variables were dichotomized to: “less-risky sexual 
behaviour practices” (risk score values ≤ -5) and “risky sexual behaviour practices” (risk 
score values > -5). McNemar’s test was then used to compare proportions of risky versus 
less-risky practices among participants who attended both visits. A “risk score change” 
variable was then generated by subtracting the baseline risk scores from 12 month risk 
scores. The, “risk score change” variable was grouped into three categories;(i) negative 
change in risk score =Decreased risky sexual behaviour practices (signifying that less-risky 
behaviour practices observed at 12 months as compared to baseline e.g. -4 score at baseline 
versus -6 score at 12 month), (ii) positive change in risk score =Increased risky behaviour 
practices (signifying that riskier behaviours practices were observed at 12 months 
compared to baseline e.g. -6 score at baseline versus -4 score at 12 month) and (iii) 0=No 
change in risk scores (signifying that same behaviour practices were observed in both visits 
e.g. -6 score at baseline versus -6 score at 12 month). Frequencies and proportions of these 
categories were summarized. 
v Outcome (c): To examine the association between baseline characteristics and changes in 
sexual behaviours in the cohort, logistic regression was performed. The “risk score change” 
variable from above was dichotomized with the first category coded 1, combining those 
who had no change in sexual behaviour and those who had increase in risky sexual 
behaviours. The second category coded 0 included those with decreased risky sexual 
behaviours. Thus, odds ratio of >1.0 estimated from the models would represent higher 
odds of increase or no change in sexual behaviours. A univariate analysis was performed 
to estimate the unadjusted odds ratio for each baseline characteristics, including the 
predicted “baseline risk score” as a binary variable. Factors whose univariate analysis 
reached a statistical significance of p<0.20 were fitted in the multivariate model using the 
backward approach. Likelihood ratio test was used to assess statistical significance. 
v Outcome (d): Poisson regression analysis was performed to determine the association 
between changes in sexual behaviours and the incidence of HIV infection. Incidence rates 
for HIV were calculated by dividing the number of new infections by the total person-
years-at risk of follow-up. In the univariate analysis, rate ratios and their associated 95% 
confidence interval were estimated for the baseline covariates as well as the predicted 
“baseline risk score” variable. Because of the few HIV seroconversion cases (44 cases), a 
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comprehensive multivariate analysis of general risks factors for HIV incidence was not 
performed. Preliminary decision was made to focus the multivariate analysis on the effect 
of changes in sexual behaviour on HIV incidence. Therefore, the multivariate model was 
first adjusted for the baseline sexual behaviour risks score as a binary variable, and 
variables that had achieved a statistical evidence at P <0.20 in the univariate analysis. 
Statistical significance of all models was assessed using likelihood ratio tests. 
Generating a sexual behaviour risk scores for predicting and estimating behaviour change. 
Table 7 presents the four sexual behaviour variables used to generate sexual behaviour risk 
scores for each woman in the Poisson regression analysis —outcome (b) describe above. The 
four variables were selected by backward elimination using P<0.20 significance level at 
univariate analysis. All models were adjusted for age, town and marital status as priori 
confounders. Positive regression coefficients indicate an increased risk of HIV while negative 
coefficients represent protection against HIV infection. Model 2 and 3 had negative regression 
coefficients for the variable transactional sex and were therefore considered implausible. The 
sexual behaviour risk score values for baseline and at 12 months were obtained from Model 1 
and generated using the following equation: 
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+ 20.70 × (56. 789:;<9=	>;	78=:	3@6;:ℎ= = 2)D
+ 21.93 × (56. 789:;<9=	>;	78=:	3	@6;:ℎ= = 3	69	@69<)D
− 20.16 × (H6;I6@	J=<	>;	K8=:	=<L = M<=)D
+ 20.56 × (N>Oℎ9>=P	=<L	>;	78=:	3@6;:ℎ= = M<=)D 
Table 7 Results of Poisson Regression model of HIV incidence used to develop sexual 









































































































Intercept -- -- -5.90(1.19) -
5.91(1.19) 
-5.90(1.19) 
Coef= Poisson regression coefficient; SE= standard error. All models were adjusted for age, town, and marital status. Model 3 adjusted for all variables i.e. 
number of partners in the last 3 months, condom use at last sex, high risk sex in past 3 months and transactional sex in the last 3 months. Model 1 adjusted 
for all variable except transactional sex; Model 2 adjusted for all variables except condom use at last sex.  
 
 47 
5.6.3 Study III: 
 Study outcomes 
a) Proportion of female sex workers aware of PrEP and proportion of female sex workers 
willing to use PrEP at the time of enrolment into the PrEPVacc registration cohort and 
the changes in these proportions after 12 months of follow-up. 
b) Association between PrEP awareness at baseline and socio-demographic 
characteristics.  
c) Proportion of female sex workers in the PrEPVacc registration cohort who have ever 
initiated the use of PrEP and the socio-demographic determinants of PrEP use. 
 Definition of measures of outcomes in Study III 
PrEP Awareness: Binary responses (Yes/No) from the question: “Have you heard about Pre-
exposure prophylaxis (PrEP) i.e the use of anti-HIV drugs by HIV negative persons to protect 
themselves from catching HIV?” 
 
PrEP Willingness: Assessed with three responses; Yes/No/Not sure to the question- “Would 
you be willing to use PrEP if it were offered to you?”. Responses of “No” and “Not sure” were 
combined to “Not willing to use PrEP” and those remaining were categorized as “Willing to 
use PrEP”. 
 
PrEP Use: Binary response (Yes/No) to the question: “Are you currently using PrEP?”. 
Participants responding “Yes” to this question during any of the three study visits (enrolment 
visit, 6 months or 12 months visits) were categorized as “Ever used PrEP” and the category 
was coded “1”. Those remaining were categorized as “Never used PrEP” and coded “0”. 
 
 Statistical Analysis 
v Outcome (a): Descriptive statistics were performed to estimate proportions of female sex 
workers who were aware of PrEP and proportions of sex workers willing to use PrEP. The 
proportions were estimated separately for participants attending the enrolment visit and 
those who attended the 12-month visit. McNemar’s Chi-squared test for paired proportion 
was used to compare the proportions at enrolment and at the 12 month visit. The paired 
analysis was restricted to participants who attended both visits. 
 
v Outcome (b): Univariate Logistic regression was used to determine demographic and 
sexual behavioural characteristics associated with PrEP awareness. Likelihood ratio test 
were used to assess statistical significance. 
 
v Outcome (c): The distribution of socio-demographic and behavioural variables was 
summarized as frequencies and proportions. This was done for the overall study population 
and separately for those reporting to have ever used PrEP and those who have never used 
PrEP. Chi-squared test for difference in proportions was used to compare proportions 
across the two groups. Variables with differences in PrEP use at p<0.05 were included in a 
multivariable logistic regression model to characterize associations. In building the 
multivariable logistic regression model, the “rule of ten” was used so as to ensure that 
covariate in the model did not exceed 10% of the primary outcome i.e 10% of the number 
of PrEP users in the cohort. Colinear variables i.e factors having the same meaning were 
excluded from the model. Adjusted odds ratio estimates from the final model, their 95% CI 




5.6.4 Study IV:  
 Study outcomes 
Study IV sought to explore the following research questions (1) What are the existing 
facilitators and barriers for contraceptive use among female sex workers? (2) How do female 
sex workers experience unintended pregnancy and how do these experiences influence their 
decisions regarding contraceptive use?  
 Grounded theory approach to data analysis  
Analysis began with line-by-line open coding of interview transcripts in accordance with the 
grounded theory approach (165, 184, 185). Line-by-line coding allowed many codes to be 
generated on everything shared by the participants regardless of the relevance to the study 
questions (165). Coding was performed using the Nvivo software (Version 12). Codes were 
developed using keywords that summarized participants’ information. Memos were written to 
describe the code, and its relevance to the research questions. In some transcripts, text was 
coded twice or more if the sentences contained more than one relevant aspect. Selective coding 
was performed by first clustering open codes into categories and then going through the 
transcripts again and deciding which initial codes made the most analytic sense when grouped 
together (165). Codes with similar meaning were merged and repetitive codes were deleted. 
For example, four codes; “a child brings prosperity”, “children bring many blessings”, 
“children bring luck”, “every child brings his/her own blessing” were aggregated to one code 
“a child is a blessing”. Collating and codifying of the initial codes was done and some codes 
were clustered and a label attached to the category.  
 
Transcripts were re-read and in certain instances codes that did not fit in a category were 
dropped to maintain focus on the research question. An example of moving from text, open 
codes and selective codes to the category are given in Figure 10. In the later stage of the 
analysis, theoretical coding was performed to explain how the codes linked with each other in 
a particular category and between categories. An overall core-category (sex work impedes good 
contraceptive behaviour) that captured most important findings of the analysis was selected 
and linked with the other categories. A model grounded in the data was constructed to illustrate 
how the codes, the categories, and the core-category related with each other and with respect 





• I was using oral contraceptives, I got 
pregnant, and I abort three times…
• I did not realize if I was pregnant because 
I was using oral contraceptives
• Sometimes I can be called by a client and 
I tell myself that I will take the pills later 
when am done with the client.
• I don’t get time and sometimes we get 
lazy to go for contraception services…we 
just say “I will go tomorrow…I will go 
tomorrow”.. but we don’t go! We 
continue with sex work!
• when they [clients]are drunk, they break 
condom intentionally….we put on two 
condoms on them but you find yourself 
wet! They break the condoms! When we 
ask them they reply “Aah… I gave you 
money! Why are you complaining?”
Informant 1 40 years old
• Using pills to prevent pregnancy
• Aborting unintended pregnancies
• Conceiving when pill is skipped  
• Admitting poor pill adherence
• Missing Family Planning clinic to 
attend clients
• Resting during Family Planning clinic 
hours
• Using condoms to prevent 
pregnancy
• Clients refusing condom use
• Failing to negotiate condom use
• Clients paying more to forgo 
condom use
OPEN CODES 
• Poor pill adherence
• Failing to access Family Planning 
clinic in the daytime
• Condom use failure
SELECTIVE CODES
CATEGORY
Sex work impedes good contraceptive 
behaviour





as a consequence of 
sex work
Core category
Sex work impedes 
good contraceptive  
behaviour
• Multiple and concurrent sexual partners
• Waiving condom use for higher pay
• Inability to negotiate condom use
• Sexual violence
• Avoiding FP clinic because of sex-work stigma
• Long waiting time in FP clinics
• Poor pill adherence 
Pregnancy as a 
blessing
• Children bring prosperity
• Motherhood negates sex-work 
stigma
• Regretting on previous 
abortions
• Keeping pregnancy because 
of fear of failure to conceive in 
the future
Pregnancy as a 
burden
• Loosing income during 
pregnancy 
• A child is a financial burden
• Partners denying child support
• Terminating pregnancy so as to 
continue with sex work




• Initiating contraceptives after 
attaining motherhood
• Accessing contraceptives during 
post-partum care
• Fearing dangers of multiple 
abortions
Figure 11 Conceptual categories and core category emerging from Grounded Theory analysis of barriers to contraceptive use among sex workers and 
experience of unintended pregnancy. 
Unintended pregnancy was expressed to be an outcome of the poor contraceptive behavior, because good contraceptive behaviour was impeded by sex work. There was an 
ambivalence attitude toward unintended pregnancy, which was perceived to be either a burden or a blessing. This perception determined the outcome of the pregnancy i.e. to 
undergo an induced abortion or keeping the pregnancy. The experience of an  unintended pregnancy, and the effect of abortion or child rearing on the sex worker’s livelihood 
and wellbeing, greatly influenced their use or commitment to use contraceptive in the future.  
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6 ETHICAL CONSIDERATIONS 
All the research studies included in this thesis involved human subjects and therefore, ethical 
clearance was sought from relevant authorities. The initial ethical approval for the PhD research 
studies was granted by the MUHAS institutional review board on April 4th 2018; Ref No. 
2018-04-04/AEC/Vol. XII/87. Application for an extension of the ethical clearance was applied 
to and received on 22nd May 2020 Ref: IRB No. MUHAS-REC-4-2020-200. The PrEPVacc 
registration cohort in which the Study I, III and IV were nested was approved by both the 
MUHAS institutional review board and National Ethics Committee at the National Institute of 
Medical Research NIMR/HQ/R.8c/Vol.I/715. Ethical approvals for the microbicide and 
vaccine feasibility studies, were granted by the Ethics Committees of the National Institute for 
Medical Research, Kilimanjaro Christian Medical Centre and London School of Hygiene and 
Tropical Medicine. 
 
Ethical concerns relating to participants in the PhD studies are discussed below. In the first 
part, description of the overall ethical issues related to the research subject is presented. 
Thereafter, an additional discussion is presented on ethical considerations relating to HIV 
standard prevention packages recommended for HIV prevention trials and other studies that 
have HIV seroconversion as the main outcome (as for the PrEPVacc registration cohort in 
Study I). Lastly ethical considerations in the qualitative study (Study IV) are described. 
 
Informed consent process; At study enrolment an informed consent process was performed by 
first explaining the study to eligible participants. Participants were given a chance to read the 
patient information sheet or, if necessary, this was read to them by a member of the study. All 
questions arising on the study objectives and process were addressed. All participants verbally 
stated that they understood and agreed to all items contained in the patient information sheet 
before being enrolled in the study. Once a verbal consent was granted, participants were asked 
to sign the informed consent form. A thumbprint was taken from participants who did not know 
how to write their name or sign the consent form. A witness was asked to sign on behalf of the 
participant who was not able to read. A study staff obtaining participant consent also signed 
the consent form in the appropriate space and affix the participant’s study identification number 
on the patient information sheet. 
 
Risk to participants: There was a psychological risk in participating in the studies due to the 
sensitive nature of the questions asked e.g sexual behaviour practices and drug use. To 
minimize this risk, the questionnaires were administered by study personnel in a private, 
confidential setting. During the interviews, participants were reminded that they could refuse 
to answer any specific question. There was also a risk of minor injury, bruising and pain due 
to the collection of blood samples. In order to minimize these risks, samples were collected by 
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trained, laboratory technician who also provided counselling and reassurance before sample 
collection. Study participants were given the name and telephone number of the study principal 
investigator and clinical coordinator should they have any question about the study or believe 
they have been injured or not well treated. 
 
Benefits to participants. The principal benefits to participants were knowing their HIV 
serostatus. Those testing HIV positives were escorted (with consent) to enrol into HIV care as 
soon as they were diagnosed to be HIV infected. Free condoms were provided as well as 
information on behaviour change and HIV prevention. Weekly participants engagement 
sessions were held to improve comprehension of the study objective. During these meetings, 
HIV risk reduction education was provided including condom use and PrEP. A Question & 
Answer session in these meetings provided participants with education which helped to 
demystify incorrect information related to HIV risk behaviour. Participants also benefited from 
screening and treatment of sexually transmitted infections as well as counselling on 
contraceptive methods. 
Voluntary participation. All participants were informed that their participation in the study was 
strictly voluntary and that they were free to withdraw from the study at any time. During the 
course of follow-up some participants opted to discontinue follow-up. Some because of 
relocation while some out of personal choice.  
 
Protection of privacy of individual and of confidential information. All interviews, counselling 
and laboratory rapid tests were conducted in private rooms. Privacy was maintained in these 
sessions by making sure that no other person was permitted in the room other than the 
interviewer and the study participant. Identification numbers were assigned to each of the 
participants and used for linking them to behavioural and laboratory data. Only aggregated 
behavioural and lab results were shared during weekly study meetings. All case report forms 
and test results were kept in locked cabinets and could only be accessed by authorized research 
member.  
 
In the incidence study (Study I), termination of participants who seroconvert to HIV posed a 
risk of compromising confidentiality. This is because, other participants continuing with 
follow-up could speculate on the HIV status of those not continuing with follow up. To 
maintain confidentiality, data of participants who seroconverted were censored but participants 
were not refrained from attending the clinic every three months, and at any time as they wanted, 
just as they would have done if they were still enrolled in the cohort.  
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6.1 HIV PREVENTION ETHICAL CONSIDERATIONS IN STUDY I 
The HIV incidence study (Study I) intended to demonstrate that the study population in the 
PrEPVacc registration cohort was suitable for participating in the PrEPVacc vaccine trial by 
detecting a “high” number of new HIV infections. Ethically, the objective of the study may 
have resulted to a perceived conflict of interest between the research team, who hope to 
demonstrate a high HIV incidence and study participants whose interest is to protect themselves 
from HIV infection. Because of this potential ethical dilemma, the guidelines for ethical 
consideration in HIV prevention trials recommends access to a package of prevention methods 
to study participants (186-192). The ethical guidelines stipulate that participants should have 
access to intervention so as to maximize benefits of HIV prevention and minimize risks of HIV 
seroconversion. Below is an outline of HIV prevention package provided in the PrEPVacc 
registration cohort. 
 
v Risk-reduction counselling was provided to study participants on their three-monthly visits. 
The counselling was provided by trained research nurses and doctors who have experience 
working in HIV vaccine trials and therefore have skills to probe for risky behaviour 
practices. Counselling sessions covered safer sex practices and reproductive health. The 
message content of the counselling was included in the standard operating procedures so 
as to ensure that the sessions were comprehensive and consistent information was given to 
all study participants.  
v Condoms. Male condoms were provided to all participants free of charge at every study 
visit. 
v Treatment of other sexually transmitted infections. Screening of sexually transmitted 
infection was performed at recruitment. Rapid blood tests for syphilis, HBV and HCV were 
performed at enrolment. Participants who tested positive for HBV or HCV were referred 
to the Hepatitis clinic at Muhimbili National Hospital for further management and follow-
up. Participants who were confirmed to be infected with syphilis, were provided with a 
drug prescription for treatment of the infection. Genital examination of vaginal ulcers 
and/or discharge was provided on demand basis. Syndromic diagnosis, drug prescription 
and/or referral to STI clinic for further testing or treatment was provided. 
v HIV pre-exposure prophylaxis (PrEP): PrEP was not provided at the study site. This is 
because PrEP was not widely available in the country and plans for implementing the PrEP 
program among female sex workers in Tanzania were ongoing. Participants were informed 
that PrEP would be not offered at the study site as part of this preliminary study. However, 
education on PrEP (what it is, how it works, efficacy and side effects) was provided to 
participants so as to improve PrEP use willingness and ensure that uptake will be high once 
it becomes available. In the PrEPVacc vaccine trial, PrEP will be provided as a study drug 
to all participants in the first 26 weeks. Thereafter, participants will be referred to access 
PrEP through the national PrEP program which is anticipated to be in place by then. 
Reflections on ethical obligations of researchers to ensure availability and access to PrEP 
among study participant is discussed in the later sections of this thesis.  
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6.2 ETHICAL CONSIDERATIONS IN STUDY IV  
An additional informed consent process was undertaken for participants included in the 
qualitative study (Study IV). Prior to the qualitative interviews, women were told of the 
objective of the study and provided with information on potential risk and benefits. A verbal 
consent was obtained from individuals willing to participate in the study and for their voice to 
be recorded. This was followed by a date, written name and signature of the researcher 
verifying that the consent was indeed taken. Participant identification numbers were used to 
label interview transcripts so as to ensure anonymity. Verbatim quotes used in reporting 
qualitative findings in this thesis as well as in the published paper do not bear respondent’s 
names so as to maintain anonymity. Throughout the interviews, participants were reminded 
and assured that the information they disclosed was confidential. After the interviews, 
participants received one-to-one counselling on contraceptive methods and were referred to 
appropriate clinics for specialized family planning services. Participants who were pregnant 
were referred to ante-natal clinics of their choice. All respondents were provided with a 




A summary of the main results in this thesis is presented in Table 8 below. 
Table 8 Summary of main findings from each PhD paper 
Study   Research Question Major findings  
I What is the one-year HIV 
incidence among female sex 
workers in the PrEPVacc 
registration cohort? What 
determines their risk of HIV 
acquisition? 
v A high HIV incidence of 3.5 per 100 person-
years at risk (95% CI 2.3-5.3/100 pyr) was 
observed after one year of follow-up. 
v The risk of HIV infection was higher among 
younger female sex workers, those using illicit 
drugs and those diagnosed with either Syphilis, 
HBV or HCV infection. However, the study 
was not powered to ascertain these associations. 
v There was good retention rate of 80% at 12 
months even though early attrition was 
observed in the second visit amounting to 36%. 
v The high HIV incidence demonstrates that the 
population in the PrEPVacc registration cohort 
is suitable for participating in HIV vaccine 
trials. 
II Do HIV-risky behaviours change 
over time among high-risk women 
enrolled in HIV prevention 
cohorts? Do these changes predict 
their HIV incidence? 
v Nearly half of the women (49%) did not change 
their sexual behaviour practices after 12 months 
of follow-up, while 25% had higher risk 
practices after 12 months. 
v There was insufficient statistical evidence to 
conclude if increases in higher-risk sexual 
behaviours was associated with a higher HIV 
incidence. 
III What proportion of female sex 
workers are aware of PrEP and 
what is the proportion of those 
willing to use it? What are the 
determinants of PrEP use among 
female sex workers? 
v More than half of the female sex workers were 
aware of PrEP (67%). Nearly all (98%) were 
willing to use PrEP if it were offered. 
v PrEP use was low (8%) mainly due to limited 
PrEP availability at the time of data collection. 
Most of the PrEP users were married and those 
who reported to engage in sex with a HIV 
infected partner. 
IV What are the existing facilitators 
and barriers for contraceptive use 
among female sex workers? Do 
experiences of unintended 
pregnancy influence the use of 
contraceptives?   
v Female sex workers face barriers in initiating 
and adhering to contraceptive use because of 
sex work stigma, inability to negotiate condoms 
and failure to access medical services at their 
convenience. 
v Financial hardships related to child rearing and 
painful abortion experiences influenced female 






7.1 RECRUITMENT OF PARTICIPANTS IN THE PREPVACC REGISTRATION 
COHORT 
Four seeds-initiated the respondent driven sampling and a total of 2,202 recruitment coupons 
were issued over three months. A total of 775 of the coupons returned met the recruitment 
criteria and were screened for study eligibility. The waves of recruitment per seed ranged from 
6 to 16 with the majority of the recruits (82%) emanating from the social networks of one seed 
(seed 2). Figure 12 and 13 provides a summary of the entire recruitment network of the four 
seeds. Socio-demographic characteristics, behavioural characteristics and the baseline 
prevalence for the HIV, HBV, HCV and Syphilis infections among female sex workers 
screened for enrolment into the PrEPVacc registration cohort is provided in the Paper I. 
(a) (b)
(c) (d)
Figure 12 Respondent driven sampling showing recruitment by seeds and recruitment 
waves 
Recruitment of each seed by (a)Baseline HIV status (b)Baseline age group 








Female sex workers in  Dar es Salaam  recruited via respondent 
driven sampling (n=775)
ASSESSED FOR ELIGIBILITY 
n=773
TOTAL ENROLLED 
v HIV negative women enrolled in the PrEPVacc Cohort (Dar –es –Salaam)  n=700
NOT ASSED FOR ELIGIBILITY
v Reported to be known HIV positive   n=2
EXCLUDED (Total=73*)
INELIGIBLE
v HIV positive n=59
v Not considered to be at risk of HIV n=13
v Had a contraindicated medical condition n=3
ELIGIBLE BUT NOT RECRUITED
v Not willing to complete questionnaire n=1
441 (63%) women attended month 6 follow-up visit 
448 (64%) women attended month 3 follow-up visit 
480 (69%) women attended month 9 follow-up visit 
562 (80%) women attended month 12 follow-up visit 
Figure 14 Screening, enrollment and follow-up of female sex workers 
in the PrEPVacc cohort, Dar es Salaam Tanzania. 
*Some women met more than one ineligibility criteria; all reasons are 
reported; therefore, the sum is greater than the number of women not 
enrolled. Attendance excludes women who missed their study visit as well as 
those terminating cohort participation due to HIV seroconversion, death or 
travel. A window of +/- 1.5 months was allowed for each visit. 
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7.2 HIV INCIDENCE AND RISK FACTORS - PAPER 1 
A total of 700 female sex workers were enrolled into the PrEPVacc registration cohort (Figure 
14). During the 12 months follow up period, they contributed a total of 609 person-years-at 
risk. The total person-years at risk was defined as time from enrolling into the cohort until when 
censored after 12 months of follow up or exit from the study owing to HIV seroconversion. 
The mean follow-up duration was 10 months and the median follow-up duration was 12 
months. There were a total of 21 HIV seroconversions within the 12-month follow up giving 
an overall incidence rate of 3.5 per 100 person-years-at risk (95% CI 2.3-5.3/100 person-years-
at risk).  
 
HIV incidence rate was high among the youngest (18-24 years) and oldest (35-45 years) age 
groups (4.31/100 person-years-at risk and 4.13/100 person-years-at risk, respectively Figure 
15), however, there was no evidence of an age effect on HIV incidence (p=0.36). We also found 
that HIV incidence was high among participants with high education levels (5.03/100 person-
years-at risk) and those who were separated/divorced/widowed (3.90/100 person-years-at risk). 
There was no statistical evidence on the effect of education or marital status on HIV acquisition 
among female sex workers in the cohort (p=0.54 and p=0.47 respectively). 
 
Participants who reported not to have used condoms at their last sexual encounter had a 41% 
higher HIV incidence compared to those who did, however this difference was not statistically 
significant (RR 1.41, 95% CI 0.57-3.50, p=0.45, Figure 15). We also found that, participants 
who were pregnant at baseline screening (which may also imply inconsistent condom use), had 
nearly twice the HIV incidence compared to their counterparts although this difference was not 
statistically significant (RR 1.83, 95% CI 0.43-7.84, p=0.45). 
 
Participants who had tested positive for either syphilis, HBV or HCV infection at baseline had 
a three times higher HIV incidence compared to those who were uninfected, though this 
difference was not statistically significant (RR 3.11, 95% CI 0.72-13.37, p=0.19). Participants 
reporting to have used illicit drugs had 27% higher HIV incidence compared to their 
counterparts, although this difference was not statistically significant (RR 1.27, 95% CI 0.37-








Figure 15 Cumulative hazard curves showing HIV incidence among female sex workers enrolled in the PrEPVacc registration cohort, Dar es 
Salaam by social demographic and behavioural characteristics 
(Log-rank test for all variables >0.05) 
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7.3 CHANGES IN HIV RISKY-BEHAVIOURS AND ASSOCIATION WITH HIV 
INCIDENCE-PAPER II 
7.3.1 Changes in risky behaviour among women enrolled in the microbicide 
and vaccine feasibility studies 
In the analysis of the cohort of high-risk women in northern Tanzania; there was a substantial 
reduction in proportion of women reporting two or more partners in each follow up visit. In 
each study visit, there was a 33% reduction in the odds for having two or more partners (OR 
0.67 95% CI 0.63-0.73, p for linear trend<0.001 Figure 16).  There was also a 43% reduction 
in the odds of women engaging in high-risk sex ( OR 0.57 95%CI 0.50-0.64, p for linear 
trend<0.001 Figure 16 ) and 47% reduction in the odds of transactional sex at each visit ( OR 
0.53 95%CI  0.49-0.57, p for linear trend<0.001 Figure 16 ).On the other hand, there was a 
23% reductions in the odds of consistent condom use with regular partner at each visit, (OR 
0.77 95% CI 0.72-0.82, p for trend <0.001 Figure 16) but there was no evidence for a change 
in the odds of consistent condom use with non-regular partners at each visit ( 0.95 95% CI 
0.87-1.03, p=0.22 Figure 16).Together with the changes observed in the decrease in number 
of partners and condom use, there was an 13% increase in the odds of higher HIV risk 
perception at each visit (OR 1.13 95%CI 1.20-1.33 p=0.01 Figure 16).  
Overall, the results indicate an increase in HIV risk perception with each subsequent study visit 












2+ partners in past
3months




Condom use with non
regular partner















Figure 16 Changes in sexual behaviours at each visit among women enrolled in the 
microbicide and vaccine feasibility studies. 
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Sexual behaviour risk scores at baseline ranged from -6.06 (less-risky behaviour) to -3.41(risky 
behaviours) with a mean risk score of -5.05(95% CI -5.08 to -5.03). On the other hand, risk 
scores at 12 months had the same range of values but a lower mean, -5.12(95% CI -5.14 to -
5.11). This lower mean indicates that on average, there were less-risky behaviour practices at 
the 12 months visit (Figure 17). Among the 1180 women who attended both the baseline and 
the 12 month visit, the proportion of women with less-risky behaviour practices at 12 months 
(defined as risk score ≤-5), was significantly higher than the proportion at baseline (97% vs 
87%, McNemar P<0.001, Figure 17). 
 
 
The mean change in sexual behaviour risk score from baseline to 12 month was -0.07 (95%CI 
-0.10 to -0.05) further signifying strong evidence of less-risky sexual practices at 12 months 
compared to baseline (paired t-test for mean difference<0.001). The observed values for the 
changes in sexual behaviour risk score ranged from -1.95(safer behaviour) to 1.93(less safe 
behaviour). Nearly half of the women (49%, 573/1180) had no change in sexual behaviour risk 
score, 25% (300 women) had an increase in the risk score and 26% (307 women) had a decrease 
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-6 -5.5 -5 -4.5 -4 -3.5
Risk scores
Risk scores predicted from risky behaviours reported at 12month
12-MONTH VISIT
BASELINE VISIT Less-risky behaviour 




Less-risky behaviour practices (≤ -5) 1013 16 1029(87%)
Risky behaviour practices (>-5) 128 23 151(13%)
TOTAL 1141(97%) 39(3%) 1180




7.3.2 HIV incidence and changes in sexual risky behaviour 
The 1378 women enrolled in the microbicide and vaccine feasibility studies contributed a total 
of 1181 person-years-at -risk, defined as, time from enrolling into the cohort until when 
censored after 12 months of follow up or exit from the study owing to death or seroconversion. 
There was a total of 44 women who seroconverted to HIV positive with an overall HIV 
incidence rate in the cohort of 3.7 per 100 person years at risk (95% CI 2.8-5.0/100 person 
years-at risk). Table 9 summarizes the factors associated with HIV incidence among women 
enrolled in the two cohorts. The HIV incidence ranged from 8.6/100 person years-at risk among 
women with risky behaviour practices at baseline to 3.0/100 person years-at risk among those 
who had less-risky behaviour practices. Women who had risky sexual behaviour risks score at 
baseline had nearly three times the risk of HIV (RR 2.86 95%CI 1.49-5.46 p=0.001). HIV 
incidence was also higher among unmarried compared to married women (RR= 5.19, 95%CI 
1.61-16.77, p=0.01) and in those who had two or more partners in the month preceding baseline 
visit (RR=2.62, 95%CI 1.28-5.38, p=0.01 Table 9).  
 
Due to the few cases of HIV seroconversion, a fully comprehensive analysis of the general risk 
factors for HIV acquisition was not performed. The final model on the association of change 
in risk score with HIV acquisition was adjusted for the baseline risk scores and marital status. 
We found that HIV risk was lower among women who had increased or no change in risk score, 
compared to those with reduction in risky sexual behaviour risk score, however there was no 
statistical evidence for the effect of changes in risky behaviour on HIV incidence (aRR= 0.88 
95%CI 0.39-2.01, p=0.76). Women who had risky sexual behaviour risks score at baseline had 
twice the risk of HIV after adjusting for other factors (aRR 1.99 95%CI 0.80-4.94 p=0.14). On 
the other hand, marital status was independently associated with HIV risk with unmarried 
women having nearly five times the risk of HIV compared to married women (aRR 4.60 95%CI 
1.42-14.95).  
CHANGES IN RISKSCORE N=1180 (col%)
No change in sexual behaviour practice
(risk score ≤-0.001)
573(49%)
Decrease in risky behaviour practices
(risk score=0)
307(26%)
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Figure 18 Distribution of change in risky sexual behaviours. 
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Table 9 Crude and adjusted rate ratio estimates for HIV incidence by changes in sexual 
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HR=Hazard ratio, CI=Confidence interval [1] Numbers may not add up to total due to missing data. [2] Estimated HR adjusted for change in risky behaviour 





7.4 AWARENESS, WILLINGNESS AND USE OF PREP AMONG FEMALE SEX 
WORKERS - PAPER III 
7.4.1 Awareness of PrEP and willingness to use PrEP 
At the time of enrolment into the PrEPVacc registration cohort, more than half of the female 
sex workers had ever heard of PrEP (67%,469/700). Those reporting to have more than 100 
partners in the past three months were 58% less likely to be aware of PrEP compared to those 
reporting to have had less than 50 partners in the same period (Unadjusted OR 0.42; 95% CI 
0.23-0.76, p<0.001, Table 10). Sex workers who reported to have been raped in the past three 
months were 78% less likely to be aware of PrEP (Unadjusted OR 0.22; 95% C I 0.15-0.33, 
p<0.001). Sex workers who were using contraceptives (which may imply access to health 
services) were twice more likely to be aware of PrEP as compared to those not using 
contraceptives (OR 2.15, 95% CI 1.55-2.98, p<0.001).  
Overall, there was high willingness to use PrEP among female sex workers in the PrEPVacc 
registration cohort. At enrolment, (98%, 684/700) of the participants said were willing to use 
PrEP if it was offered. Of the remaining 16 participants: four reported not to be willing to use 
PrEP and 12 female sex workers were not sure if they would use it. There was no change in 
PrEP willingness after 12 months follow-up in the cohort (98% vs 96% McNemar test p=0.84). 












(col%) (row%) (row%) (LRT) 
Overall 700 231 469 --   
Age(years)           
<25 328(47) 120(37) 208(63) 1 0.1 
25-34 271(39) 77(28) 194(72) 1.45(1.03-2.06)   
35-45 101(14) 34(34) 67(66) 1.14(0.71-1.82)   
Education           
None/Incomplete Primary 83(12) 36(43) 47(57) 1 0.09 
Complete Primary/Incomplete 
secondary education 
480(66) 155(32) 325(68) 1.61(1.0-2.58)   
Complete secondary or higher  137(20) 40(29) 97(71) 1.86(1.05-3.28)   
Condom use at last sex         
0.39 Yes 281(40) 98(35) 183(65) 1 
No 419(60) 133(32) 286(68) 1.15(0.84-1.59) 
Number of partners in the past 
3 month 
          
≤50 89 (13) 15(17) 74(83) 1 <0.001 
51-100 233(33) 93(40) 140(60) 0.31(0.16-56)   
>100 377(54) 123(33) 254(67) 0.42(0.23-0.76)   
Rape in the past 3 months         
<0.001 Yes 120(17) 75(63) 45(38) 0.22(0.15-0.33) 
No 579(83) 156(27) 423(73) 1 
Contraceptive use         
<0.001 Yes 448(64) 120(27) 328(73) 2.15(1.55-2.98) 
No 252(36) 111(44) 141(56) 1 
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7.4.2 Use of PrEP 
A total of 57 HIV negative female sex workers in the PrEPVacc registration cohort (8%, 
57/700), reported to have ever initiated the use of PrEP at any point during the 12 months 
follow-up period. Nearly all of the female sex workers who had ever used PrEP (86%,49/57) 
reported to have received PrEP from a Non-governmental organization clinic while 11% (6/57) 
reported to have had received PrEP from a friend – possibly a peer educator within the female 
sex workers community. We found that marital status was strongly associated with PrEP use 
whereby; female sex workers who were married/co-habiting were four time more likely to use 
PrEP (aOR 4.19, 95%CI 1.44-12.18 Table 11), while those separated /divorced /widowed were 
twice more likely to use PrEP (aOR 2.38, 95%CI 1.17-4.83, Table 11) as compared to female 
sex workers who had never been married. We also found that female sex workers who reported 
to have had sex with a HIV infected partner were associated with four times the odds of using 
PrEP (aOR 3.98, 95% CI 1.20- 13.15, p=0.04, Table 11). However, we did not find any 
statistical association between PrEP use with number of partners, consistent condom use or 
with experiences of rape. 
 
Table 11 Multivariable analysis showing factors associated with PrEP use 
Characteristic EVER used 
PrEP/Subtotal 
(row %) Adjusted OR P-value  
Relationship status        
Never Married 40/594(7) 1 
0.01 
Married /Cohabiting 5/22(23) 4.19(1.44-12.18) 
Separated/Divorced/Widowed 12/84(14) 2.38(1.17-4.83) 
Number of partners in the past 3 months 
≤120 31/426(7) 1 
0.52 121+ 25/273(9) 1.20(0.68-2.13) 
Sex with HIV infected partner in the past 3 months  
No/Don’t Know 52/683(8) 1 
0.04 Yes 4/16(25) 3.98(1.20-13.15) 
Condom usage during transactional sex 
Always use 6/42(14) 1 
0.34 
Sometimes use 47/622(8) 2.49(0.45-13.66) 
Never uses 2/34(6) 1.19(0.27-5.26) 
Rape in the past 3 months 
No 42/579(7) 1 
0.15 Yes 14/120(12) 1.65(0.85-3.21) 
OR adjusted for marital status, number of partners in the last three months, sex 





7.5 FACILITATORS AND BARRIERS FOR CONTRACEPTIVE USE – PAPER IV 
7.5.1 How sex work impedes good contraceptive behaviour 
Unintended pregnancy was expressed to be an expected outcome of sex work, because sex 
work impeded good contraceptive behaviour. On one hand, sex workers expressed awareness 
of contraceptives and had knowledge on how contraceptives worked, but on the other hand, 
they expressed frustration over how consistent contraceptive use was hindered by the nature of 
sex work. They reported failure of contraceptive use because of poor adherence leading to some 
women conceiving when using contraceptives. Failure to initiate, continue or appropriately use 
contraceptives was expressed as a fault at an individual level, but it seemed to be embedded in 
contextual factors that influenced contraceptive use e.g. gender power dynamics in negotiating 
condom use, sex work stigma in family planning clinics.  
Waiving condom use for a higher pay from clients. Although condom use was generally 
desired by the sex workers who wished to protect themselves from not only pregnancy but also 
from sexually transmitted infections including HIV, women expressed that, it’s use risked low 
payment from clients. With casual partners, sex workers waived condom use so as to get a 
higher pay. With non-commercial partners or long-term regular partners condoms were waived 
to maintain good relations for financial and emotional security. 
“There some clients with whom I want to use protection, but he may force you to have 
sex without it (condom)…... This is your work and you need the money, so you do it. 
And this, (unintended pregnancy) is the result of it (unprotected sex).…”[Informant 8, 
29 years]. 
 
Sex work stigma from health workers, impedes initiation and continuation of non-barrier 
contraceptives. Sex workers tried to mitigate inconsistent condom use, by opting to use non-
barrier contraceptives (e.g., birth control pills, Depo-Provera, implants and intrauterine 
devices). However, sex workers expressed frustration on the stigma they received when visiting 
the family planning clinic. This stigma resulted in avoidance of health services. 
“…you can go to the hospital to get implants and they may speak to you harshly. You 
can’t stop the person from talking negatively because they are doctors and you might 
not get the services. They can tell you do this or do that or you are not seated properly… 
Instead of telling you politely they just provoke you… But it’s not just to me, even to 
my friends, some of my friends wanted to insert implants but they stopped…. There is 




Sex work routine impedes adherence to non-barrier contraceptives. Women explained that 
contraceptives were readily available in health centres but long waiting time and inconvenient 
clinic hours made them not to seek services. Contraceptive services are offered in the clinics 
during daytime and often closing at 3pm, when sex workers are likely to be sleeping/resting in 
preparation for working at night. Consequently, they fail to adhere to monthly clinic visits for 
refills or injections and therefore miss or skip contraceptive use for a month or more. Pill 
adherence was hampered by the tendency to forget taking pills when intoxicated after drinking 
alcohol, oversleeping because of working late hours, or skipping the pill when called by a 
client. On the other hand, sex workers expressed that the side effects of contraceptives such as 
nausea, heavy menses etc. interfered with their work –– risking loss of income. One would 
discontinue contraceptive or skip the pill to avoid side effects, and thus risking pregnancy. 
“I don’t get time and sometimes we get lazy to go for contraception services, that’s 
why we get unexpected pregnancies!…..We just say I will go tomorrow....I will go 
tomorrow, but we don’t go. We continue with our sex work….Sometimes a client might 
come at your working place and you may forget [taking the pill]because you are in 
hurry so you forget to take them.”  [Informant 1 40 years]. 
 
7.5.2 How experiences of unintended pregnancy influence commitment to 
good contraceptive behaviour. 
 
Having experienced the hurdles of unintended pregnancy, sex workers initiated contraceptive 
use and committed to consistent use and good adherence. Irrespective of the pregnancy 
outcome i.e. having an abortion or keeping the pregnancy, these women perceived unintended 
pregnancy experience as a wakeup call to contraceptive use. Postpartum initiation of 
contraceptive use was common among sex workers who reported to have learnt about 
contraceptives and being offered to initiate contraceptive use after delivery. 
 
Female sex workers were also more likely to initiate contraceptive use post-delivery due to the 
myth of infertility associated with contraceptive use before childbirth. Sex workers expressed 
concerns that initiating contraceptive use at younger age resulted in infertility in the future and 
therefore it was safer to use contraceptives after having a child. This misconception was a 
reason why most women had not previously used hormonal contraceptives, even though they 
knew the risk of unintended pregnancy in sex work. 
 
“When I had my first child, I didn’t use contraceptives, I started after having the second 
child because they were close (spaced). I was not aware that there is such a thing as 
family planning.., and I didn’t know if I could conceive again within such a short time! 
… When I conceived for a second time that is when my mind was opened! Therefore, 
when I attended clinic they advised me to start using family planning immediately after 
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delivery. Given the challenges I went through, the difficulties of raising those children, 
after delivery I wasted no time, honestly speaking! The same day when I started post-
natal clinic, I also started using contraceptives! Nurses should promote 
(contraceptives), provide education to emphasize people on using it especially soon 
after delivery! They should not keep quiet! They should educate someone until she 
understands” [Informant 5,28 years]. 
 
Sex workers expressed painful abortion experience following an unintended pregnancy. They 
also expressed worries of having to go through another abortion in the future. Some expressed 
fear that abortion could result to infertility in the future. With this, they expressed commitment 
to use and adhere to contraceptives so as to prevent unintended pregnancy. 
“ We do not look further and consider what will happen later. So, you just do it (abort) 
because it’s important to you at that moment. But at the end of the day you can decide 
to stop and when you want to have a child, you don’t get one. It might be because of 
the multiple abortions in the past… may be the cervix has experienced some problem 
like getting loose… or perhaps you were only meant to have one or two children and 







The findings in this thesis demonstrated the HIV incidence, and described the sexual and 
reproductive health behaviours among high-risk females recruited for participation in HIV 
prevention trials in Tanzania. Specifically, the results described the recruitment, screening, 
enrolment and retention of female sex workers living in Dar es Salaam into the PrEPVacc 
registration cohort. The discussion below provides an account of the suitability of the female 
sex worker enrolled in the PrEPVacc registration cohort for participation in HIV vaccine trials, 
in particular the PrEPVacc vaccine trial. Where appropriate, findings on HIV incidence and 
changes in sexual risky behaviour from the cohorts in the northern Tanzania will be used to 
discuss expected changes in sexual risky behaviour in the PrEPVacc registration cohort.  
This discussion section includes a reflection on the following issues (a) the estimated one-year 
HIV incidence and its suitability for HIV efficacy trials (b) changes in HIV risky behaviour 
during cohort participation and if these changes influence the HIV incidence in the cohort (c) 
awareness, willingness and use of HIV pre-exposure prophylaxis among female sex workers 
and how this may affect evaluation of efficacy in HIV vaccine trials (d) barriers to contraceptive 
use among female sex workers and a reflection on ways to minimize unintended pregnancy 
during participation in HIV vaccine trials. 
 
8.1 DETECTING A HIGH HIV INCIDENCE IN HIV PREVENTION TRIALS  
The analysis in Study I found that female sex workers living in Dar es Salam have a high HIV 
incidence of 3.5 per 100 person- years at risk (95% CI 2.3-5.3/100 person-years at risk). The 
HIV incidence was not precise or higher than the expected incidence of 4.0/100 persons-years-
at risk but it was within the expected margin from the sample size estimation (in Table 3). 
Importantly, this HIV incidence is sufficiently high to confirm that female sex workers living 
in Dar es Salaam are indeed a HIV high-risk population suitable for participation in the 
PrEPVacc HIV vaccine trial.  
The HIV incidence of 3.5 per 100 person-years at risk estimated in the Study I was similar to 
the HIV incidence of 3.7 per 100 person-years-at risk (95% CI 2.8-5.0/100 person-years at risk) 
estimated in the cohorts from northern Tanzania (Study II) even though there was a 10 years 
difference between recruitment into the cohorts (2008 for cohorts in northern Tanzania versus 
2018 for the PrEPVacc registration cohort). This finding indicates that women who sell sex, 
either as direct sex workers (Study I participants) or in-direct sex workers (Study II 
participants) are (unfortunately) still a HIV high-risk population in Tanzania and therefore a 
suitable population for HIV efficacy trials. 
 
The estimated HIV incidence in the PrEPVacc registration cohort was similar to the incidence 
of 3.8 per 100 person-years at risk (3.5-4.2/100 persons-years-at risk) estimated among women 
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living in areas of high HIV incidence in Kenya, South Africa and Zambia (90). The HIV 
incidence in the PrEPVacc registration cohort was lower than the 5 per 100 person-years at risk 
HIV incidence estimated in the placebo arm of a PrEP study among African women (193). 
However, in this study there were no HIV incident cases among participants from Tanzania—
possibly because the trial at the Tanzanian site was initiated just a few months before the trial 
unexpectedly ended due to lack of efficacy. The HIV incidence in the PrEPVacc registration 
cohort was also lower than the 10.4% estimated in a cohort of female sex workers in Iringa 
Tanzania (only incidence proportion was reported in the Iringa study and information on person 
years at risk was not provided). The higher HIV incidence among female sex workers in Iringa 
can be explained by the high HIV burden in the general population in that region (HIV 
prevalence of 11.2% in Iringa vs 4.3% in Dar es Salaam (25)). 
The PrEPVacc registration cohort sample size was powered to detect a HIV incidence with an 
expected 95% confidence interval extending from 1.0 to 7.0 per 100 person years at risk (Table 
3). Although the observed incidence was within the margin, it is also possible that this incidence 
is lower than the actual HIV incidence in the wider female sex worker community in Dar es 
Salaam. This is because cohort participants have better access to HIV prevention interventions 
unlike female sex workers in the community. For the same reason, the HIV incidence in the 
PrEPVacc registration cohort may decline over time as participants become better engaged 
with the cohort and receive access to condoms, risk reduction counselling, treatment of sexually 
transmitted infection and PrEP upon its availability. The HIV incidence in the cohort will also 
decline as most at-risk participants become HIV infected early and exit the cohort, leaving 
those at lower risk continuing with cohort follow-up. As of March 1st 2021, the HIV incidence 
in the PrEPVacc registration cohort had decline to 2.7 per 100 person years at risk (95% CI 
1.9-3.8/100 persons-years-at risk). This observation of a declining HIV incidence is not 
uncommon in HIV prevention trials and has been reported in other vaccine preparedness 
cohorts (92, 93, 171, 194, 195). Because of this, open cohorts instead of closed cohorts are 
recommended for HIV vaccine preparedness cohorts. Additionally, it is worth mentioning here 
that the HIV incidence in the cohort could have been higher if the cohort did not suffer from 
early attrition by younger female sex workers who are known to have a higher HIV incidence. 
The impact of the loss-to-follow up bias on the HIV incidence and the preference for open 




8.2 CHANGES IN SEXUAL RISKY BEHAVIOURS IN HIV PREVENTION TRIALS 
In the analysis of the cohort of high-risk women in northern Tanzania (Study II), the mean 
change in sexual behaviour risk score from baseline to 12 months was -0.07 (95% CI -0.10 to 
-0.05, paired t-test for mean difference<0.001). These results provide strong evidence of less-
risky sexual practices at 12 months compared to baseline. Enrolment into the cohort was 
associated with reduction in the number of sexual partners, selling sex and having high risk sex 
at each follow up visit. There was an increased HIV risk perception among participants at each 
visit. Consistent condom use with regular partners was significantly lower at each follow-up 
visit but there were no changes in consistent condom use practices with non-regular partners  
 
The analysis in Study II did not confirm the hypothesis that risky sexual behaviour in the cohort 
increases over time and were associated with higher HIV incidence. There was no statistical 
evidence of an increased HIV incidence rate among women with no change/increased sexual 
behaviour risk scores at 12 months after adjusting for their baseline sexual behaviour (p=0.79). 
Contrary to subjective expectation and biological plausibility, women with no 
change/increased in risk score at 12 months, had a lower point estimate of HIV incidence 
compared to those with reduced sexual behaviour risk score although this finding could have 
been due to chance (aRR 0.89 95% CI 0.37-2.10). This finding could also partly be explained 
by the fact that the multivariate model suffered from low power due to the few HIV 
seroconversion cases; and that, the composite risk score used to quantify risky behaviours was 
based on self-reported behaviour and had left out a substantial number of risky sexual 
behaviour variables. 
 
Taken together, the implications of findings from Study II to the PrEPVacc registration cohort 
are that: (i) Risky behaviour practices decrease after 12 months of follow up especially among 
those who had more risky practices at recruitment; and (ii) The reduction in risky behaviour 
may not affect the HIV incidence estimated after 12 months of follow up. It is possible that this 




8.3 THE USE OF PRE-EXPOSURE PROPHYLAXIS (PREP) IN HIV 
PREVENTION TRIALS  
Findings from Study III indicate that, majority of female sex workers in Dar es Salaam are 
aware and willing to use PrEP to protect themselves from HIV acquisition. However, there 
were very few female sex workers who had ever initiated the use of PrEP, possibly because it 
was not widely available in the country at the time of data collection. The use of PrEP as a 
biomedical HIV prevention intervention is appealing to female sex workers because it offers 
them control on its use (98, 196-198). 
High PrEP awareness and willingness was sustained among participants possibly because of 
the repeated PrEP education provided in the weekly cohort engagement meetings. This finding 
could suggest the need for repeated PrEP education among PrEP users in the future PrEPVacc 
vaccine trial so as to sustain PrEP adherence. This is important because PrEP studies among 
female sex workers as well as among other high-risk groups have shown lower PrEP 
continuation even when high PrEP willingness was expressed (100, 104, 105, 199-201). One 
reason cited for PrEP discontinuation among individuals was not being in the “risk season” or 
taking a “PrEP break” (199, 202, 203). This is expected among female sex workers because 
they are known to occasionally take breaks from commercial sex. In support of this, evidence 
from PrEP implementation studies have suggested that PrEP should not be a lifelong 
intervention, only to be used during high-risk period and that adherence should be insisted 
during the high-risk period (200, 203-205). Therefore, continued education on PrEP will offer 
opportunities for re-assessment of HIV risk so as to promote willingness and adherence to PrEP 
during high-risk periods.  
 
We found that PrEP use was higher among sex workers engaging in sex with an HIV infected 
partner. This finding is consistent with others that have reported good PrEP adherence among 
sero-discordant couples (206-208). The findings further show the helpfulness of PrEP as a 
woman-controlled HIV prevention intervention in instances where negotiating condom use 
with a partner (especially a regular or intimate partner) is not possible or fails (82, 209-211). 
Another plausible explanation for this observation would be behaviour disinhibition as a female 
sex worker may knowingly engage in sex with a HIV positive partner because of the assured 
protective effectiveness of PrEP. Encouragingly studies have reported that risk compensation 
is of limited concern among PrEP users and that the use of PrEP may actually increase risk 
perception and encourage safer sexual behaviour practices (98, 100, 102, 193, 196, 197).  
 
This observation also serves as a reminder that in the future PrEPVacc vaccine trial, risk 
reduction counselling sessions should remind participants that PrEP (and the vaccine products) 
should not replace condom use or other behaviour modification. Participants should also be 
reminded of the persistent HIV risk, sexually transmitted infections and unintended pregnancy 
associated with unprotected sex.  
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8.4 PREGNANCY AND CONTRACEPTIVE USE AMONG PARTICIPANTS IN 
HIV PREVENTION TRIALS 
There were a total of 46 pregnancies over the year of follow-up in the PrEPVacc registration 
cohort. Pregnancy is of concern because in most efficacy trials, pregnancy is an exclusion 
criteria and study product is usually discontinued once pregnancy is confirmed because of the 
unknown unintended effects of the product on pregnancy or foetus. Preventing unintended 
pregnancy among female sex workers is also important because it reduces their HIV 
vulnerability perpetuated by financial burdens of child rearing (77). The pregnancy incidence 
observed in the registration cohort may provide a guess of participant attrition attributable to 
pregnancy in the future PrEPVacc vaccine trial.  
 
The risk of unintended pregnancy can be minimized by advocating for the use of dual 
contraceptives especially the use of long-acting reversible contraceptives. The analysis in Study 
I showed low use of long-acting reversible contraceptives such as implant and inter-uterine 
devices. Additionally, qualitative findings in study IV indicated that there was inconsistent use 
and regular switching of Depo Injections and oral contraceptive pills. For instance, some sex 
workers reported to have conceived when they had skipped/missed an oral contraceptive pill 
or Depo Injections. This indicate that even though contraceptive use may have been reported 
in Study I, discontinuation or skipping a pill is very common. For this reason, use of long-
acting reversible contraceptives is recommended among female sex workers because these 
methods are less prone to incorrect use, discontinuation and frequent switching (80, 85, 90). 
 
A notable finding from the analysis in Study I was that, the very group that is at risk of HIV 
acquisition (18 to 25 years old) was also the group who had the highest pregnancy incidence. 
Therefore, long-acting contraceptives in this group should be advocated in the trial so as to 
minimize study attrition. The findings from the qualitative study (Study IV) are disconcerting 
as it was noted that younger female sex workers (who are also likely to be null parous) may not 
agree to use contraceptive in fear of a popular myth that initiation of contraceptive at an early 
age causes infertility. There were also some indications from Study IV that the desire for 
motherhood could be a barrier to contraceptive use since having a child was highly regarded 
as a “blessing”. Because of the desire for motherhood reported among participants it may be 
problematic for the participants to opt for HIV vaccine product instead of motherhood. In other 
HIV vaccine trials that involve females, researchers suggested the need to involve male partners 
so as to reduce pregnancy (92). However, this may be challenging in the PrEPVacc registration 
cohort as sex workers have multiple sexual partners. 
 
Findings from Study IV highlighted the need for integrating contraceptive services within the 
same location that offers HIV services to female sex workers e.g within the PrEPVacc study 
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site. This is because female sex workers face barriers at an individual or structural level that 
impede access to contraceptive services. These factors include sex work stigma in medical 
facilities as well as failure to attend family planning clinics during their clinic operating hours. 
Contraceptive services at the PrEPVacc study site will have to offer multiple contraceptive 




8.5 METHODOLOGICAL CONSIDERATIONS 
This section discusses the key methodological limitations and consideration in the PhD studies.  
8.5.1 Epidemiological considerations in quantitative studies (Study I, II, III) 
 The Role of chance (random error) 
v In both study I and II the number of HIV seroconversion were few. This limited the 
statistical power of the studies to determine factors associated with HIV seroconversion. 
This can be evident with wide confidence intervals in the univariate and multivariate 
analyses for HIV risk factors (Table 9 and in Paper I). This limitation was more prominent 
in Study II since the study was a secondary analysis of data. The sample size in study II 
was powered for the aims of the parent cohorts and therefore underpowered to detect 
significance level for the research questions in this thesis. 
 Selection Bias 
v The use of respondent driven sampling: Participants included in studies I, III and IV were 
recruited using a peer-chain referral sampling technique which is a non-probability 
sampling technique. Respondent driven sampling was intentionally used so as to penetrate 
networks of hidden female sex worker populations. Respondent driven sampling employs 
the use of incentive system whereby recruits are reimbursed for their time and transport 
upon completion of interviews and also for successfully recruiting eligible peers. 
Consequently, recruits may have been coached on responses so as to meet eligibility criteria 
or participants may have preferentially invited peer sex workers whom they knew to be 
HIV negative. This may explain the high eligibility rate (700 eligible out of 775 screened) 
and the low HIV prevalence observed relative to the expected (8% HIV prevalence 
observed compared to the 15% HIV prevalence in a recent survey). In attempts to minimize 
this risk, a reasonable amount of incentive money was set in consultation with research 
teams at MUHAS who had conducted respondent driven sampling among female sex 
workers in Dar es Salaam around the same period. The team had conducted a formative 
study ahead of recruitment to approximate travel cost of participants to the research site at 
MUHAS. The incentive amount was also approved by the MUHAS institutional Review 
Board. Additionally, recruits arriving at the site were further vetted by a research assistant 
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who was a peer female sex worker and had experience of screening sex workers for 
participation in survey using a respondent driven sampling method.  
 
v Lost-to-follow up bias: There was evidence of differential follow-up in both study I and II. 
In study I, we found that, compared to those remaining in the study, participants who did 
not attend the 12 month visit (n=138), were younger and reported more unprotected sex 
with two or more partners (Table included in Paper II). It is possible that HIV incidence in 
the study was underestimated because those loss-to-follow up were arguably at a higher 
HIV acquisition risk. To minimize attrition in the PrEPVacc registration cohort, a selected 
group of “tracers” are used to trace peers who miss visit. Tracers were selected based on 
whether they lived or work in the same neighbourhood as that of a participant who was 
lost-to-follow-up or missed a visit. Together with this, contact and locator information of 
the participants were constantly updated to facilitate tracing. In study II, women who did 
not attend the 12-month visit (n=194) were younger, unmarried and arguably “higher-risk”. 
It is likely that reduction in sexual behaviours was underestimated as a result of early lost 
to follow up by higher-risk women because the proportion of women with higher number 
of partners, those involved in transactional sex and high-risk sex was significantly higher 
among women dropping out than those remaining in the cohorts. A sensitivity analysis 
using multiple imputation to determine the effects of missing data in both study I and II 
might have been performed, but are beyond the scope of this thesis. 
 Information Bias &Measurement errors 
v Social desirability bias is of concern since sexual behaviours in Study I, II and III were 
based on self-reports. Social desirability bias is common in HIV research and has been 
extensively documented in literature (215-218). Participants may have falsely under-
reported or over-reported behaviours so as to please the research staff. For example, in 
Study II, under-reporting of sexual partners or over-reporting condom use in the 12 months 
visits as compared to the baseline visit may have resulted in an apparent reduction in risky 
sexual behaviours. This may have consequently biased the observed odds ratios and over-
estimated the reduction in risky behaviour. During data collection the study made attempts 
to minimize reporting bias by making the questions neutral, assuring participants of 
confidentiality and having frequent follow-up visits. 
 
v Measurement error in estimating behaviour change (Study II): The predicted sexual 
behaviour risks scores in Study II were based on only four sexual behaviour variables and 
may have been inadequate in providing reliable estimates for the values of the individual’s 
risk. Because of the few HIV seroconversion cases in the dataset, the development of the 
risk score used to quantify behaviours was difficult. Selection of the best model was based 
on a decision to ensure that the model coefficients provided the most plausible estimates 
albeit the model already suffered from low power. It is possible that the Models B and C 
which were not used because they had “implausible” coefficients (e.g., coefficients that 
predict condom use to be harmful instead of protective against HIV acquisition) could have 
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been different if they were generated in a larger dataset which has more HIV events e.g., at 
least 100 HIV events. 
 
v Limitations of midpoint imputation for HIV seroconversion date: In both Study I and II, 
midpoint between latest-negative and earliest positive test date was assumed to be the HIV 
seroconversion date. Although the mid-point assumption is commonly used in prospective 
cohort and can give reasonable approximation of the incidence date (219, 220), it can also 
be subjected to errors once participants start to miss scheduled HIV test dates (221). This 
is because the missed test dates are likely to extend the width of the censoring interval. The 
use of the midpoint assumption is expected to be accurate when testing rate is more than 
80% (221). This limitation is more likely to be pronounced in Study I than in Study II 
because of moderate testing rate in follow-up visit in Study I (~60%) compared to study II 
(~80%). The effect of the midpoint imputation for HIV seroconversion date can be noted 
in Figure 15 as HIV infection events are concentrated in the middle of the observation 
period (around the 6 month visit) and a sharp decrease towards the end of the 12 month 
observation period. An alternative approach to minimize this would be to use the Monte 
Carlo methodology to impute a single random infection date within the censored interval 
(221). However, this type of analysis was beyond the scope of this thesis. 
 Confounding 
v In Study II, follow-up period was relatively short (one year) to effectively observe any 
actual changes in behaviours. The study was also unable to assess if the changes in sexual 
risky behaviour observed were due to changes in the women’s life circumstance or induced 
by the risk reduction counselling and other interventions provided in the cohorts. 
 
v There was no information collected on the male partners in study I & II and therefore the 
analyses are not able to explore why unprotected sex, high-risk sex and transactional sex 
were not associated with HIV acquisition as expected. 
 
v Residual confounding: In study II, residual confounding may have been introduced because 
“increased risky behaviour” and “no change in behaviours” were categorized together as 
the outcome. This was done with an assumption that, women who had no change in 
behaviour included those who retained high risk behaviours at 12 months. However, it is 
likely that this group consisted of women who retained low-risk behaviours. In study II, 
residual confounding may have been introduced by adjusting for the composite effect of 
the baseline sexual behaviour risk score in the multivariate analysis. For instance, previous 
studies have reported that number of partners, anal sex, sex during menstruation and rape 
to be individually associated with a higher HIV risk among female sex workers (172, 222). 
However, this was not observed in the study because these variables were included in the 
composite variable. This may have consequently biased the observed associations between 
the baseline sexual behaviour risk score and HIV incidence towards the null value.  
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8.5.2 Trustworthiness considerations in the qualitative study (Study IV) 
This section provides an evaluation of Study IV trustworthiness based on criteria by Lincoln 
and Guba (223). In each criterion, a brief description of the criteria is provided and a discussion 
given on how the criteria were achieved in the study. 
 Truth/Credibility: 
Credibility in qualitative research seeks to discern the truth-value of the study findings by 
ensuring that the multiple and subjective realities of the study informants is captured (165). In 
Study IV, the following strategies were used to achieve credibility. 
v Prolong engagement: I had a chance of meeting the informants in two or more occasions 
before commencement of data collection (interviews). First during the scheduled baseline 
and follow-up interviews as part of the parent cohort study procedure (PrEPVacc 
registration cohort) and later during participant engagement meetings (weekly educative 
sessions held as part of improving comprehension on HIV vaccine trials). Engagement with 
the informants was also possible after the qualitative interviews as the participants attended 
subsequent follow up visit in the PrEPVacc registration cohort. I was also part of the study 
team who conducted the quantitative interviews for the PrEPVacc registration cohort. Data 
collected in these interviews included questions on the use and preference of contraceptive 
methods. This provided me with a chance to explore contraceptive use among sex workers 
other than those already participating in the qualitative interviews. I also took part in 
delivering pregnancy test results to the participants as part of the PrEPVacc registration 
cohort study visit procedures. This provided me with first-hand experience on how 
participants reacted to a positive pregnancy test results because the majority had not 
intended to become pregnant. In all these encounters, I took personal notes on observations 
relating to the study question. 
 
v Triangulation: Sampling of study participants i.e women who were pregnant was done by 
obtaining a pregnancy test results from the PrEPVacc registration cohort laboratory records 
and counterchecked with the PrEPVacc registration cohort database. Socio-demographic 
characteristics, contraceptive use and number of children reported by the informants were 
confirmed from the cohort study database. Because the participants continued to attend the 
study site even after their qualitative interviews, it was obvious that not all positive 
pregnancies reached full-term during the course of follow up whether due to spontaneous 
or elective abortions. 
 
v Peer - debriefing: By engaging the PrEPVacc registration cohort research team on the 
objective of the qualitative study, provided an opportunity for study nurses to share 
experiences on how women would react to the pregnancy positive results. For example, 
one of the study nurses recounted on how women who received a positive pregnancy test 
would not believe the results. Others would cry, seeking consolation and advise from the 
nurses on what to do. This was consistent with what was narrated by some informants in 
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the in-depth interviews. The informants reported on how they got advice from the study 
nurses which had an influence in their decision to initiate or adhere to contraceptives in the 
future. 
 
Presentation of preliminary findings from the analysis was done to fellow qualitative 
researchers and experts in the Grounded Theory Approach. This was done as part of course 
work in Qualitative Data analysis at Umea University. Codes, categories, choice of core 
category and the emerging model were discussed. This provided me a chance to receive 
inputs and comments from those outside the research process.  
 
v Use of “deviant cases”: While the qualitative study aimed only at participants enrolled in 
the PrEPVacc registration cohort who had positive pregnancy test, two "deviant cases" 
were included to further explore theories raised in the interviews. One of the cases was a 
younger woman who had never been pregnant. She provided views on contraceptive and 
abortions from younger women with no pregnancy experience. The other case was of a 
HIV positive woman, mother of three children who had unintended pregnancy and was 
unsure of the paternity of the child. This participant was included to further explore the 
theory that, HIV positive sex workers are less likely to use condoms, (therefore more likely 
to get pregnant) and that they are more likely to abort the pregnancy in fear of mother-to-
child HIV transmission. However, this theory was not supported by the subsequent 
interviews and therefore not further pursued. 
 Applicability/Transferability 
Applicability refers to how relatable findings in the study are to other settings so that theories 
developed can be used to explain similar phenomenon in other setting or when designing 
interventions. Applicability can either be achieved through theoretical/analytical generalization 
or naturalistic generalization. Analytical generalization is achieved by purposively sampling 
which ensures that, selected study participants provide a comprehensive, complete and 
saturated accounts to the theory developed. On the other hand, naturalistic generalization is 
achieved if a study context (time and place) are detailed enough so that the reader is able to 
judge the suitability of generalizing the theories developed into his/her context (165) . 
 
In Study IV, informants were selected purposively to ensure that their diversity i.e age, 
education, number of children and duration in sex work, allowed for richer variation of the 
theory developed (183). Inclusion of deviant cases (one HIV positive sex worker and a sex 
worker who had never been pregnant) allowed to saturate theories developed. Additionally, 
since the interviews dates were spaced from the date of the pregnancy test, by the time 
participants were interviewed, some had already undergone an abortion, some were still 
pregnant and some had already given birth. This diversity allowed to understand how 
experiences and decision around unintended pregnancy differed ensuring that theories 




Because Study IV was nested within the PrEPVacc registration cohort which had a different 
sampling technique, naturalistic generalization of the theories developed to another context 
may be challenging. The PrEPVacc registration cohort included sex workers who were 
recruited by peer chain-referral sampling through members in their social network using the 
respondent-driven sampling technique. It is likely that, sex workers included in the PrEPVacc 
registration cohort (the sampling population for Study IV) were more networked, and possibly 
had better health seeking behaviour (including contraceptive use) compared to those in their 
wider community. Therefore, this may limit the applicability of the study findings to female 
sex workers in other contexts. 
 Consistency/Dependability 
Consistency in qualitative research refers to the ability of the researcher to recognize the 
epistemological nature of the qualitative research and therefore be able to account for the 
evolution of theory developed (165). The epistemological feature of qualitative research means 
that, the relationship between the researcher and informant is interactive, inseparable and 
greatly influences the knowledge created (165). With this, repeatability of findings from 
qualitative research is not possible as it is the case in quantitative research. The qualitative 
researcher is bound to adopt the research process based on his/her interaction with participants 
and during the analysis process, hence an emergent design (183). For this reason, keeping a 
trail of the evolution of the research process is recommended so as to achieve 
consistency/dependability. 
 
Throughout the course of Study IV, a number of changes were made. These include, revision 
of research question, designing of the interview guide and its modification over time, changes 
in data collection period — a decision was made to conduct the interviews further away from 
the pregnancy test result so as to minimize the influence of the interview on the participant’s 
decision-making process. Throughout this process, correspondence with co-investigators 
through emails, meeting minutes and revised drafts were maintained so as to provide a trail on 
why decisions were made.  
 
During data collection, the interview guide evolved with subsequent interviews so as to allow 
covering a range of concepts and also accommodate new theories based on the responses 
provided by the preceding interviews. With this, the theoretical sensitivity increased as more 
data were collected (165). As a result, later interviews were more focused, covering more 
concepts but at a risk of narrow and specific responses (165, 183). For example, as noted in the 
earlier chapters of this thesis, the interview with the first informant (In-depth interview 
conducted in January 2019), covered fewer concepts but provided a long and detailed narration 
of the issues whereas the interview with the tenth informant (In-depth interview conducted in 
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June 2019) covered more concepts but provided narrower responses. However, there is also a 
risk that this extensive period of data collection may have resulted to inconsistency meaning 
and that questions may have not covered same areas for all participants (183). 
 
During data analysis, memos were made documenting different stages of the Grounded Theory 
analysis process. Sketches of models developed were kept and revisited when changes were 
made so as to retain perspective of data from the transcript in relation to the research question. 
 Neutrality/Confirmability 
Confirmability of qualitative research refers to the ability of the conclusions presented being 
grounded in the data when observed by a third party (inquiry auditor), i.e findings are observed 
to be neutral, independent of the researcher’s subjectivity (165). Although this criteria conflicts 
with the epistemological assumption of qualitative research i.e the researcher and informant 
both make the data, neutrality in qualitative research is sought from the standpoint of the data 
presented and not the researcher. 
 
Study IV used the Grounded Theory analysis approach. Line-by-line coding that was 
performed ensured that theory was developed from narrations of the informants. Minimal 
abstraction was used during labelling of codes so as to maximize neutrality of the data. 
Importantly, while a conceptual framework (Health Belief Model) had been used at the study 
design phase and to develop the interview guide, this framework was note used in theoretical 
coding and developing of the theories during analysis. This allowed me to maintain neutrality 
to the data and ensure an inductive process was used for theory development. Quotations used 
in the writing of the study results reflect how findings had emerged from the data and show 
that there was minimal abstraction.  
 
Information on my gender, academic qualification, role in the PrEPVacc registration cohort, 
data collection process and analysis were submitted to the journal for the Study IV publication 






v The PrEPVacc registration cohort has demonstrated that it is possible to identify, enrol and 
follow up female sex workers living in Dar es Salaam for participation in HIV vaccine 
trials. We found that participants in the PrEPVacc registration cohort had a high HIV 
incidence rate, low pregnancy rate and high retention. This is an important step for site 
preparedness in anticipation of the future PrEPVacc vaccine trial. (Study I) 
 
v There was an overall reduction in individual risky behaviours over time, and that HIV risk 
was higher among women who had riskier behaviours at during recruitment. There was 
insufficient evidence to ascertain the association between changes in sexual behaviour and 
HIV incidence at 12 months. (Study II) 
 
 
v Female sex workers living in Dar es Salaam reported to be largely aware of PrEP and were 
willing to initiate PrEP. However, PrEP use was low reflecting limited access to PrEP in 
the country. (Study III) 
 
v Initiation and adherence to contraceptive use among female sex workers is impeded by a 
number of contextual factors such as gender-power inequality, poverty as well as sex work 
stigma. The results show the need to integrate contraceptive services within HIV programs 
servicing female sex workers in their work areas. In such programs, providers should 
initiate contraceptive counselling and offer wide range of non-barrier contraceptives that 





10 POINTS OF PERSPECTIVE 
This section includes a reflection of the findings from this thesis to the wider field of HIV 
epidemiology, HIV preventive trials and HIV prevention programs in Tanzania.  
 
Section 10.1 includes a reflection on the trend of HIV epidemiology in Tanzania. Section 10.2 
discusses the considerations in the designs and conduct of HIV biomedical prevention trials. 
Specifically, and with reference to the PrEPVacc vaccine trial, I discuss on the complexity of 
designs in HIV trials in an era where a highly effective prevention intervention (antiretroviral 
based PrEP) is increasingly becoming available. Lastly, in section 10.3, I highlight on how the 
available evidence on contraceptive use among female sex workers can be used to inform 
delivery of the PrEP program in Tanzania and also inform the need for long-acting PrEP agents 
which offer an adherence advantage. 
 
10.1 REFLECTIONS ON THE TRENDS OF HIV EPIDEMIOLOGY IN TANZANIA 
The high HIV incidence estimated among high-risk females in Study I and II indicate that there 
is persistence high HIV incidence in this population despite the decline of the HIV burden at 
population level in Tanzania. As noted earlier, the HIV incidence of 3.5 per 100 person-years-
at risk estimated in the Study I is fairly similar to the HIV incidence of 3.7 per 100 person-
years-at risk estimated in Study II despite the two cohorts having a 10 years difference in time. 
Contrary to this, the HIV prevalence in the general population at the national level has decline 
from 5.7% in 2007/2008 to 4.8% in 2016/2017 (25, 26). A similar declining trend in the HIV 
prevalence has also been observed in Dar es Salaam region where Study I was conducted (6.9% 
to 4.3%), and two of the three regions where cohorts for Study II were located (Shinyanga 7.4% 
to 5.5%; Kilimanjaro 3.8% to 2.2). However, this was not the case for Geita where there was 
an increase in the HIV prevalence from 4.7% to 5.2%. Notwithstanding the changes in 
demographic and the increased longevity of people living with HIV (due to the wide 
availability of anti-retroviral therapy) which can partly explain the HIV prevalence; the 
sustained high HIV incidence among high-risk females in Tanzania could be an indication of 
the HIV epidemic transition to an endemic phase. In a HIV endemic phase, HIV is concentrated 
in core groups e.g. Key and vulnerable populations including female-sex workers who have 
limited access to or engagement with services (4, 224).  
 
The persistent high HIV incidence also highlights vulnerability of female sex workers and that 
in the past decade, the existing HIV prevention programs have not been tailored to the needs 
of this population. Poor access and/or uptake of available interventions may have been impeded 
because of sex work stigma, inconvenient of operating hours in the health care facilities or 
possibly because the available interventions are not under the control of females (e.g condoms). 
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This underlines the need for a targeted HIV service delivery model to female sex workers and 
the need for female controlled HIV prevention interventions such as PrEP so as to achieve HIV 
epidemic control in the country. 
10.2 REFLECTIONS ON EPIDEMIOLOGICAL AND ETHICAL CONSIDERATIONS 
IN HIV PREVENTION TRIALS 
10.2.1 Preference for open cohorts over closed cohorts in HIV prevention 
trials.  
As stated earlier in the discussion section, decline in HIV incidence is usually expected in a 
cohort of high-HIV risk individuals. This is partially due to the standard prevention package 
offered to participants which includes risky reduction counselling. This was observed in results 
of Study II whereby, sexual risky behaviours decline over time— even though the study was 
not powered to detect the association between the decline and HIV incidence. HIV incidence 
is also expected to decline because those at greatest HIV risk get infected early and exit the 
cohort. Early attrition of those at higher risk of HIV infection also contributes to the decline of 
HIV incidence in the cohort—as was observed in Study I with loss-to-follow up significantly 
higher among younger female sex workers.  
 
The decline of HIV incidence over time in the cohort may have implication in the recruitment 
and conduct of the PrEPVacc vaccine trial. This is because, progressively over time a pool of 
low-risk study participants remains in the cohort. If this low-risk group is enrolled into the 
vaccine trial, it may result in lack of efficacy results because the overall HIV incidence will be 
low. Thus, incidence studies are only useful to identify and prepare groups at risk for trials 
rather than to serve as trial populations 
In order to minimize the declining HIV incidence in the cohort, continuous enrolment into the 
preparedness cohort i.e an open cohorts approach will allow to maintain a relative stable HIV 
incidence over time. As of 2020, the PrEPVacc registration cohort is open, with recruitment of 
new participants ongoing as others exit the cohort for various reasons. Participants in the 
PrEPVacc registration cohort have exited the cohort because of; personal choice, permanent 
relocation out of Dar es Salaam, death and study termination due to loss to follow-up after 
multiple attempts of tracing. Continuous recruitment of new participants from different 
catchment areas will enable accrual of high-risk individuals into the PrEPVacc registration 
cohort and subsequently the PrEPVacc vaccine trial. Another strategy to maintain high HIV 
incidence in the cohort would be to allow participants who remain seronegative to exit the 
cohort after a specified period e.g., two years as they may be considered “low risk. This strategy 





10.2.2 Use of PrEP as a standard of prevention in HIV prevention trials 
The recently revised UNAIDS ethical considerations in HIV prevention trials published in 
January 2021, oblige researchers to ensure access to PrEP as part of the standard prevention 
package (187). In the PrEPVacc vaccine trial, oral PrEP (Truvada or Descovy) will be provided 
as a study drug up to week 26 when the vaccine induced immune response is expected to have 
peaked (refer PrEPVacc study schema Figure 8). Thereafter, participants will be referred to 
access PrEP via the national PrEP programme. Because availability of PrEP via the national 
programs differs among countries participating in the PrEPVacc vaccine trial, use of PrEP may 
vary among participants across trial sites. This may raise an ethical concern that standard of 
care package varies among participants in the same trial. For the MUHAS site, plans are 
underway to enact the MUHAS Clinical Trial Unit as a PrEP dispensing site under the Ministry 
of health’s national PrEP program. Once this is established, trial participants and even non trial 
participants will have access to PrEP. This would help avoid any conflict of interest that staff 
may have in referring participants to access PrEP elsewhere as promotion of PrEP may be 
perceived to underpower the vaccine efficacy results. It is likely that having access to PrEP at 
the trial site would improve PrEP uptake as Study III showed that there was high willingness 
to use PrEP among participants. 
 
There is an ethical concern in conducting trial among those not adherent to PrEP because 
effectiveness of oral PrEP is directly influenced by adherence. We noted from Study IV that 
sex work impedes use of daily oral contraceptive pill. This finding may indicate that adherence 
to daily oral PrEP in the trial will be sub optimal. Contrariwise, vaccine efficacy results 
somewhat relies on participants non-adhering to PrEP so as to increase the number of incidence 
cases powered to detect efficacy. This may pose an ethical predicament for researchers who 
are also required to advocate for good PrEP adherence. Fortunately, PrEP adherence in the 
PrEPVacc vaccine trial will be monitored by a urine test for the presence of Tenofovir. This 
adherence monitoring would allow the study team to objectively monitor and document PrEP 
adherence so as to offer adherence support. 
 
Another potential ethical concern related to PrEP in the PrEPVacc vaccine trial is on providing 
and insisting participants to use daily oral PrEP while there is growing evidence on long-acting 
PrEP agents that offer adherence advantage and efficacy over oral daily PrEP. This has been 
shown in a recent concluded HPTN 084 trial which compared daily oral PrEP (Truvada) to 8 
weekly injectable PrEP (Cabotegravir) among females at high risk of HIV infection. In the 
HPTN 084 trial there were 36 new HIV infection in the Truvada arm compared to only four 
new HIV infection among those receiving the injectable PrEP (113). This may pose an ethical 
concern that participants in PrEPVacc vaccine trial are not receiving the “state-of the art” HIV 
prevention modality as mandated by the ethical guidelines for HIV prevention trials. 
Cabotegravir injectable PrEP has been shown to be more effective than oral daily Truvada, 
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because it minimizes some of the challenges associated with oral daily PrEP pill use. It is 
administered less frequently, more discrete therefore not associated with judgment and stigma 
for being seen with PrEP pills. At the moment the PrEPVacc vaccine trial may be ethically 
justified to offer oral daily PrEP since the adherence benefit of Cabotegravir injection is a recent 
discovery, the drug is not licensed in Tanzania and commercial production is not yet been 
widely scaled. However, this rationale may probably not be viable over the course of the trial 
and the study may have to be flexible to adopt new PrEP agents or other HIV prevention tools 
has they become widely available.  
 
10.2.3 Complexity of HIV prevention trial study designs in the era of PrEP  
The availability of PrEP which can be up to 100% effective if taken correctly, raise the concern 
that individuals who are successfully using PrEP may not be considered a high HIV risk 
population. On the other hand, current HIV biomedical prevention trials (including vaccines, 
monoclonal antibodies and new antiretroviral based PrEP) use active control designs instead 
of placebo i.e all trial participants receive an anti-retroviral based PrEP as an ethically obligated 
standard package for HIV prevention. Consequently, HIV incidence in HIV prevention trials 
is bound to be very low rendering the study statistically underpowered to detect efficacy of the 
vaccine products. Large samples size or longer follow up periods would be needed in vaccine 
trials and therefore more resources. Because of this, design of HIV prevention trials has become 
complex in order to account for the epidemiological and ethical considerations needed to prove 
efficaciousness of new products in the context of known high effectiveness of PrEP. 
 
Currently three strategies known as “Compare” “Layering” and “Combine” are being used in 
randomized clinical trials for new HIV prevention product while taking into account PrEP as 
an active control (169). In the first strategy “Compare” participants are randomised to receive 
either a new PrEP product or an existing PrEP product (Truvada). In this case, the new drug 
under research is intended to be used as an alternative to Truvada. For example in the HPTN 
083 and HPTN 084 trials a new Injectable cabotegravir was compared to existing oral Truvada 
(113, 114) whereas in the DISCOVER trial daily oral Descovy as a new PrEP formulation was 
compared to the existing daily oral Truvada (108, 225) . In all these studies participants 
received a PrEP agent and no one received a placebo so that the ethical consideration of 
ensuring everyone receive PrEP as standard package of prevention was adhered (187). The 
second strategy “Layering” whereby everyone in the trial has access to PrEP and on top of that 
participants are randomized to receive either the experimental product or placebo. PrEP is not 
offered as a study drug but is made available through the study clinic. For example, in the 
Mosaico Trial (HVTN 706) (119) and The AMP studies (HVTN 703/HPTN 081 (133) and 
HVTN 704/HPTN 085 (132)) participants have/had access to PrEP but not mandated to use it. 
This strategy is intended where the new HIV prevention products that will be used together 
with PrEP in case the PrEP agent is not sufficiently effective e.g., because of poor adherence 
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to oral pill intake. Lastly the third strategy is “Combine” whereby participants are randomized 
to receive the new product together with PrEP or PrEP alone. This strategy is intended for 
products planned to be used in combination with PrEP.  
 
The PrEPVacc vaccine trial is complex with all the strategies described above used at different 
time points. In essence the “combine strategy” will be used to asses efficacy of vaccine products 
given in combination with PrEP. However, in the first 26 weeks while the body has yet to 
generate immunity from the vaccine products, efficacy of Descovy will be “compared” to 
Truvada in reducing HIV incidence i.e “compare strategy” will be used. After the 26th week 
PrEP will be withdrawn (as a study drug) but participants will access it through the study clinic 
i.e like in the “layering strategy”. The challenge with the combine/layering strategy in the 
PrEPVacc vaccine trial, is that evaluating efficacy of the vaccine products on top of the PrEP 
efficacy will be difficult if uptake and adherence to PrEP is high among participants.  
 
Future trial designs will also have to use long-acting PrEP agent such as injectable or 
implantable PrEP as a HIV prevention standard because of their adherence advantage over oral 
PrEP. The use of long-acting PrEP agents in the future trials will results in more ethical and 
epidemiological challenges because of the high effectiveness and compliance associated with 
these products. First, trials will require large sample size of more than 100,000 participants 
because of the low expected HIV seroconversion rate (169). Second, it may ethically be 
deemed futile to conduct research for new HIV prevention products in settings where HIV 
prevention success has been achieved by the long-acting PrEP agents (6, 169). Nevertheless, 
HIV prevention trials may have scientific merit in risk populations where long-acting PrEP 
may be ineffective because of safety, intolerance or other reasons. Development and testing of 
long lasting, preventive HIV vaccines is still needed and essential to end the HIV/AIDS 
pandemic(10). 
10.3 REFLECTIONS ON FINDINGS FROM CONTRACEPTIVE USE AND HOW 
THEY CAN INFORM PREP USE AMONG FEMALE SEX WORKERS 
Some of the findings on contraceptives use practices among sex workers in Study IV can be 
used to inform PrEP uptake in the PrEPVacc vaccine trial and in the PrEP program at large. 
First, it is important that PrEP should be provided in a sex-worker friendly clinic and preferably 
integrated with contraceptive and/or HIV testing services. This is so as to avoid experiences of 
sex-work stigma as those reported from sex workers accessing family planning clinics in Study 
IV. The use of PrEP is also associated with the stigma of being labelled HIV infected or 
promiscuous (226-228) therefore there is need to ensure that PrEP is provided in a sex-worker 
friendly environment so as not to discourage potential users. The integration of PrEP, 
contraceptive use and HIV services is widely recommended and has been shown to improve 
demand and uptake of PrEP (229-232). Secondly, long-acting PrEP delivery methods would 
be ideal for sex workers so as to avoid problems of daily pill taking such as incorrect use, 
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skipping pills, taking pills when intoxicated with alcohol or discontinuation as observed in the 
case for oral contraceptive pills in Study IV. Already such PrEP delivery models are underway 
(6, 233, 234) including monthly oral Islatravir pill (117) , monthly Dapivirine vaginal ring (109, 
112)and monthly Cabotegravir injectable PrEP(113). Having these long-acting PrEP tools will 
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